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SUMMARY
This thesis concerns the synthesis and chemical characterisation 
of some novel synthetic and semi-synthetic narcotic analgesics.
The thesis is divided into four chapters.
Chapter one concerns the synthesis of the 8-arylmorphan derivative 
8-acetoxy— 2-methyl-8-phenyl-2-azabicyclo [3,3*l]nonane, in eleven 
steps from hydroxyphenylacetic acid. This agent was examined for 
analgesic activity in rodents but was essentially inactive.
In chapter two the synthesis of some pethidine reverse ester and 
fentanyl analogues of 3-substituted quinuclidines is described.
The fentanyl analogue 2-benzyl-3-(N-propionylanilino)quinuclidine 
was found to be approximately one tenth as active as morphine in 
rodent tests, but all other derivatives proved inactive.
Chapter three concerns the preparation of an optically pure series 
of (-)-5a,l*-methyleneoxy-6,7-benzomorphans, obtained from natural 
dihydrocodeinone. This series of compounds was exemplified by the 
(-)-8-hydroxy-5a, 1 * -methyleneoxy-2-methyl-9a-propyl-6,7-benzomorphan 
which had a level of analgesic activity two thirds that of morphine 
in rodent tests. However, the other members of this series of 
compounds only exhibited low levels of activity.
The synthesis, resolution and chemical characterisation of the 
(+) and (-) antipodes of the l-trans-2.6-trimethvl analogue of the 
reverse ester of pethidine is undertaken in chapter four. This study 
was part of a larger analysis (undertaken elsewhere) on the effect of 
alkyl substitution in the piperidine ring of A-phenylpiperidine 
analgesics. The more active antipode was the dextrorotatory one, which 
was shown to have the configuration 2S,6S, and these observations are 
consistent with the broad body of data secured from structure-acrivity 
analysis of compounds in this class..
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1GENERAL INTRODUCTION
The structure of morphine 0.1 was elucidated in the 1920s by





Since then, a large number of synthetic and semi-synthetic 
narcotic analgesics have been produced and several have gained 






However, despite these advances, morphine and its derivatives 
(codeine, heroin) remain amongst the most clinically important 
drugs for the treatment and relief of chronic pain.
2Many classes of synthetic analgesics, including 0.2 and 0.3.
3
contain fragments of the structure of morphine and it is 
therefore important to consider its structural aspects more fully.
Although morphine has 5 chiral centres (denoted • ), the steric 
constraints of the B/C ring junction (cis only) restrict the 
number of possible stereoisomers to 16. Morphine obtained from 
natural sources (the poppy Papaver somniferum) is exclusively the 
single laevorotatory enantiomer represented by 0.1. It is in this 
isomer that the analgesic activity resides. As is the case with 
other classes of synthetic analgesics, one optical isomer is 
generally responsible for the analgesic properties of the 
racemate. When the derivative retains the bulk of the morphinoid 
skeleton as in the morphinan (0.4) or 6,7-benzomorphan (0.5) 
series, it is the isomer which corresponds to the absolute 






3The dextrorotatory enantiomer of morphine has no analgesic 
properties and this is generally true of the other dextrorotatory 
morphinoid species. However, these compounds may possess other
4
pharmacological activity, for example, anti-tussive properties.
Once the structure of morphine had been elucidated, work began to 
produce modified derivatives in which the aim was to retain the 
analgesic properties of morphine and dissociate these from its 
undesirable side effects.
Before further discussion of these derivatives, the 
pharmacological effects of morphine should be noted. Morphine 
produces its analgesic effect by increasing the threshold at which 
pain is perceived. This is accompanied by a sedative, euphoric 
effect. Its major undesirable actions are respiratory depression 
and tolerance, which leads to the most widely known side effect of 
morphine : addiction.
Work on the production of new componds which might be free of, or 
have a reduced level of, side effects, was advanced by the 
discovery of the morphinan levorphanol (0.6) This was found to 
be several times more potent than morphine, but with no greater 






Other classes of synthetic analgesics have since produced 
compounds which have shown some dissociation of desirable and 
undesirable properties. These classes include the 
6, 7-benzomorphans, the arylmorphans, the phenylpiperidines, the 
3,3-diphenylpropylamines and others. To illustrate their 
structural relationships to morphine, an example of each class 





6 . 7 - BENZOMORPHANS 
0.7 METAZOCINE
5 -ARY LMOflPHANS 
5(m-HYDROXYPHENYL)MORPHAN 
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This thesis consists of four chapters, each of which relates to 
synthetic work carried out in a different area of the broad field 
of central analgesics research.
Chapter One concerns the synthesis of the 2-azabicyclo [3,3*1] 
non-8-one 0.10 and its subsequent conversion to the 8-phenyl- 
8-acetoxy derivative 0.12 via the alcohol 0.11.5
This particular azabicyclic skeleton (morphan) constitutes the 
central fragment of the morphine skeleton which has been drawn 
(dotted) surrounding 0.10. 0.11 and 0.12 below.
Me
0U0 R+Ri=0 
< L U  R=Ph R1=OH 
L I ?  R=Ph R1=OCOMe
Although certain J5-arylmorphans possess significant analgesic 
activity (0.8 being equipotent with morphine) no _8-arylmorphans 
have been examined for activity. The synthesis of 0.12 in Chapter 
One of this thesis is an attempt to examine the possibility of 
producing 8-arylmorphans as potentially active analgesics and was 
originally part of a larger scheme to examine the effect of 
repositioning the aromatic substituent to alternative sites on the 
morphan skeleton.7
Chapter Two concerns the synthesis of some potential narcotic 
analgesics based on quinuclidine 0.13.
5 L 1 3
Quinuclidines may be considered as analogues of piperidines in 
which both rings are constrained in boat conformations. Narcotic 
analgesics based on 4-substituted piperidines are numerous, 









Quinuclidines analogous to a constrained conformation of 3-aryl 
piperidines are synthetically accessible via 3-quinuclidone 0.17.
Any analgesic activity exhibited by these analogues e.g. 0.18 may 





The 6,7-benzomorphans are well documented as an important class of
narcotic analgesics, and includes derivatives with pure agonist
3
and mixed agonist/antagonist properties. Since their invention
in the 1950s, a large number of synthetic variations have been
effected in an effort to separate their desired analgesia from
physical dependence and other undesired properties.10 Optical
resolution producing pure optical isomers is another approach.11
Certain optically pure (-)-6,7-benzomorphans have been shown to be
without physical dependence capacity (PDC) in rhesus monkeys. In
particular, the (-)-5-methyl-9a-propyl-6,7-benzomorphan 0.19 has
12been shown to warrant further investigation. Chapter Three
concerns the synthesis of a novel and optically pure laevo series










0.20 and its derivatives were produced by a four stage conversion 
of natural dihydrocodeinone 0.21. rather than by using a more 
conventional synthetic route followed by optical resolution of the 









1 Me ? /
HO
SCHEME_0 .^1
0 ^ 2 1
0^ .20
11
Chapter Four concerns the preparation, resolution and 
stereochemical characterisation of the (+) and (-) antipodes of 








This study was part of a larger analysis (undertaken elsewhere) on 
the effect of alkyl substitution in the piperidine ring of
14 15
4-phenylpiperidine analgesics. * The overall analysis has 
defined the absolute orientation of methyl substituents that 
favour or have a minor influence on ligand-receptor interactions 
and thus influence analgesic activity. These allowed orientations 
are illustrated in 0.23. Following this model, the 2 antipodes of 
0.22 (0.24 and 0.25) should show a large potency difference, with 












To confirm that the model is valid for 0.22. its initial 
synthesis, followed by resolution of the 2 antipodes, was 
undertaken. This was followed by X-ray crystallography of one 
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CHAPTER ONE
2-AZABICYCL0N0NANE INTRODUCTION
Morphan, [2-azabicyclo [3,3»l]nonane (1.1)1, constitutes an 
important structural fragment of morphine 1.2. and as such is a 
potential substrate for elaboration into more complex, novel 
molecules with potential analgesic activity.
Various methods have been used for the synthesis of morphans over 
the past 40 years. Several of these have been chosen and 
illustrated with example syntheses.
synthesise the basic morphan skeleton utilised the lactamisation of 
ethyl cis-3-aminocyclohexane acetate 1.3. followed by reduction of 
the resulting lactam 1.4. either catalytically or with lithium 
aluminium hydride (LAH).
H
1 .1 1 . 2
1 2In the late 1940s ’ , the earliest successful attempts to
1.3 was prepared via 2 similar routes, both of which utilised 
m-nitrobenzaldehyde as precursor. The first (illustrated in scheme 
l.l1) started with the reduction of m-nitrobenzaldehyde 1.5 to the 
corresponding alcohol 1.6 with aluminium isopropoxide. Conversion 
of 1.6 to the alkyl bromide 1.7 took place quantitatively with HBr 
in benzene. Conversion of 1.7 to the cyano derivative 1.8 followed 
by acid hydrolysis gave the acid 1.9. Esterification with 
ethanolic HC1 gave ethyl m-nitrophenylacetate 1.10. Catalytic 
hydrogenation of 1.10 over Adams catalyst in glacial acetic acid 
gave the required ethyl cis-(3-aminocyclohexvl)acetate 1.3. Use of 
ethanol as solvent in place of acetic acid gave only the aromatic 
amine 1.11 presumably due to poisoning of the catalyst by 1.11. 
Larger scale reductions in glacial acetic acid yielded mixtures of 
ester 1.3 and lactam 1.4. Ester 1.3 was also partially lactamised 
to 1.4 by heating and subsequent distillation. LAH reduction of
1.4 in dioxan gave the required 2-azabicyclo[3,3*1]nonane 1.1 .
The overall yield of 1.1. from m-nitrobenzaldehyde was 
approximately 6Z.
1^6 R=CH2OH 
J L Z  R=CH2Br 
1^8 R=CH2CN 
JL9 R=CH2C02H 







SCHEME 1 .1  1
18
2
The second synthesis (shown in scheme 1.2 ) again utilised 
m-nitrobenzaldehyde as starting material. Treatment with benzoyl 
chloride and sodium cyanide gave m-nitro-O-benzoylmandelonitrile 
1.12. Alcoholysis of 1.12 in ethanolic HC1 gave ester 1.13. 
Catalytic hydrogenation of 1.13 over Raney nickel in ethanol at 
iL2(0°C in the presence of sodium carbonate gave largely the 
N-ethvl-cis-3-aminocyclohexaneacetic acid 1.14. which iactamised on 
heating to 215°C to give N-ethylmorphan 1.1a.
Catalytic hydrogenation of 1.13 over Raney nickel in tert-butanol 
gave the lactam 1 .4 directly. 1.4 was hydrogenated over a copper 
chromite catalyst to give the required 2-azabicyclo[3.3#1]nonane 
1.1. The overall yield of 1.1 from m-nitrobenzaldehyde in this 
sequence was approximately 10Z.
These 2 schemes offer a similar approach to the synthesis of 
morphan 1.1. However, they suffer from 2 major disadvantages. 
Firstly, reduction of the aromatic nitro/amino ester gives a 
proportion of aminocyclohexyl ester in the trans configuration 






U 2  R=CH(CN)OCOPh 











Approximately 25 Z of the unwanted trans aminocyclohexyl ester was 
produced in schemes 1.1 and 1 .2 , further contributing to their 
overall low yields.
The second disadvantage of these syntheses is that the final 
product 1.1 is devoid of functional groups, restricting the 
production of more complex structures with potential analgesic 
activity.
Methods available for the synthesis of functionalised 2-azabicyclo 
[3*3,l]nonanes will now be discussed.
The first, illustrated in scheme 1.3 and attempted in this 
2a
laboratory allows the incorporation of a hydroxyl group in the 
final product at position 8 . Nitration of ethyl A-hydroxyphenyl 
acetate 1.15 yielded predominantly the m-nitro derivative 1.16.
The catalytic hydrogenation of 1.16 using a range of experimental 
conditions (catalyst, solvent, temperature and pressure) led to the 
reduction of the aromatic ring in most cases. However, cyclised 
products were not obtained either directly from the reduction, or 
after heating or distillation of the reduced products.
The required 8-functionalised morphan was eventually obtained by 
another route (see discussion) and consequently this lactamisation 
method was not pursued further. However, it has been reported here 
for completeness as a potential route to functionalised morphans. 
Oxidation of 1.19 to the keto derivative would allow more complex 
structures to be developed, for example, compounds produced via 
Grignard reactions (see discussion).
22
OH







1 . 1 8
SCHEIVE 1 .3  2a
3
In the mid 1950s , an approach to the synthesis of the 9-hydroxy 
morphan 1.29 utilised the lactamisation of 
cis-ethyl 3-amino-2-hydroxycyclohexane acetate 1.25.
o
j c o 2e \
NH2 , NH
1 . 2 5 1 . 2 8 1 .2 9
However, unlike the earlier examples, the intermediate amino ester 
1.25 was not obtained via reduction of a suitable aromatic 
precursor. Instead, 2-carbethoxycyclohexanone 1.20 was chosen as 
starting material (scheme 1.4)., Alkylation of 1.20 with sodium 
ethoxide and ethyl bromoacetate gave diester 1.21. Alcoholysis of 
1.21 with sodium ethoxide in ethanol followed by ring closure and 
hydrolysis of the intermediate open chain triester 1 .21a gave the 
mono acid 1.22. Replacement of the carbethoxy group in 1.22 by 
oximation gave oxime 1.23. Catalytic hydrogenation of 1.23 over 
palladium on carbon followed by treatment with ethanolic HC1 gave 
amino ester hydrochloride 1.2A. Sodium borohydride reduction of 
1.24 in ethanol gave the alcohol 1.25 which lactamised on heating 
to 200°C. The isomeric alcohol 1.26 was obtained by hydrogenation
over platinum on carbon using H2O as solvent. However 1.26 could 
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25
Instead, treatment of its hydrochloride with sodium acetate in 
ethanol afforded the acetate 1.27. which could be induced to 
lactamise by heating to give 1.28.
LAH reduction of the resulting lactam 1.28 gave the 
9-hydroxy-2-azabicyclo [3,3,l]nonane 1.29 in 232 yield. The overall 
yield of 1.29 from 2-carbethoxycyclohexanone was approximately 
0.52.
26
In the early 1970s^, an alternative method of producing a
7-functionalised 2-azabicyclo [3,3,l]nonane skeleton was reported, 
utilising an intramolecular Michael-type cyclisation of 
2-oxo-A-(N-alkylaminoethyl)cyclohexene 1.35 (scheme 1.5).
Starting from 3,5-dihydroxyphenylacetic acid 1.30. catalytic 
hydrogenation over rhodium on alumina in aqueous sodium hydroxide 
afforded 1,3-cyclohexanedione-5-acetic acid 1.31 (mono-enol form). 
Amide formation on 1.31 required the protection of the enolic-OH 
(by esterification) to prevent reaction with the amine. Once 
protected, reaction with methylamine followed by hydrolysis of the 
protecting group gave amide 1.32. Enol ether 1.33 was obtained by 
refluxing 1.32 in methanol containing .jj-toluenesulphonic acid 
(p-TSA). LAH reduction of the amide function in 1.33 gave amine 
1.34. Hydrolysis in aqueous acid, followed by treatment with 
sodium hydroxide, then effected cyclisation via 1.35. to give 
2-methyl-2-azabicyclo [3*3.1]nonan-7-one 1.36. The overall yield 
from 3,5-dihydroxyphenylacetic acid was 312. The N-substituent 
could be varied by use of other amines at the amide formation 
stage.
H1 . 3 0
1.36
Ihi/le
1 31 R=OH R, =H 1 . 3 4  R=OH R1=OMe
1 32 R=NHVIe R,=H 1 . 3 5  R=0 R1=H
1 . 3 3  R=NHMe R,=Me
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In the mid 1970s^, an alternative method of synthesis, yielding an
8-functionalised morphan, utilised the solvolysis of enol ether 
(and ethylene ketal) N-chloramines in trifluoroacetic acid and 
methanol. The N-chloramines were prepared in 7 steps from 
hydroxyphenylacetic acid 1.37. (Scheme 1.6 illustrates one of the 
2 major reaction pathways used.)
Esterification of 1.37 with ethanol and B^SO^ gave ethyl ester 
1.38. Catalytic hydrogenation of the aromatic ring in 1.38 over 
Raney nickel in ethanol at high pressure and temperature gave 
ethyl 4-hydroxycyclohexyl acetate 1.39. Oxidation of the hydroxyl 
group in 1.39 with acid dichromate gave ketone 1.40. Reaction of 
1.40 with trimethylorthoformate and methanol in the presence of 
jj-TSA protected the keto group as its enol ether 1.41. Reaction of 
the ester group with methylamine and sodium methoxide in methanol 
gave amide 1.42 which was reduced to the amine 1.43 with LAH in 
THF. Quantitative conversion to the N-chloramine 1.44 was achieved 
by treatment of 1.43 with sodium hypochlorite solution. Solvolysis 
of 1.44 in trifluoroacetic acid gave cyclic enol ether 1.45. which 
after hydrolysis afforded N-methyl-2-azabicyclo[3#3.1]non-8-one 
1.46.
Use of the ethylene ketal protecting group in place of the enol 
ether similarly afforded 1.46. The overall yield in each case was 





















Another solvolytic method of synthesis of a 6-functionalised 
morphan utilised the solvolysis of 4-(N-chloromethylaminoethyl) 
cyclohexane 1.48 in dilute acid (sbheme 1.7®).'v
Thus, N-chlorination of 1.47 gave the chloramine 1.48. On 
treatment with aqueous acid this rearranged to 1.49. Treatment of 
1.49 with base gave the isomeric epoxides 1.50 and 1.51. 1.51 was
not isolated but cyclised to the required
6-hydroxy-2-azabicyclo[3*3.1]nonane 1.52. In practice, treatment 
of 1.48 with 1M gave a 1:2:4 mixture of starting amine 1.47.
morphan 1.52 and epoxide 1.50. 1.52 was obtained in 37Z yield
after purification.
Starting amine 1.47 might also be produced using an abbreviated 
version of scheme 1.6 by hydrolysis and reduction of 1 .43.
NRMe




1 . 4 8  R=CI 1 .51
2CI -
1 . 49 1 . 5 0
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A notable example of a series of synthetic analgesics based on the
2-azabicyclo [3*3#l]nonane system are the 5-arylmorphans 1,53.
meNR
1^53 1.54
Several of these, notably 1.54. have been investigated and
found to be highly potent in rodent tests. The synthesis of 
5-(m-hydroxyphenyl)-2-methyl-2-azabicyclo[3.3,l]nonane 1.54 is 
illustrated in scheme 1.8.^ Alkylation of 2-(m-methoxyphenyl) 
cyclohexanone 1.55 with 2-chloro-N,N-dimethylethylamine gave 20Z of 
wanted C_-alkylated product 1.56 and 60Z of O-alkylated product 1.57 
from which 1.55 could be regenerated by acid hydrolysis.
Bromination of 1.56 in acetic acid followed by ring closure of the 
resultant a-bromo ketone 1.58 in aqueous ammonia, gave the wanted
5-(m-methoxyphenyl)-9-oxo-2-methyl)morphan methobromide 1.59. Dry 
distillation gave the base 1.60. which was converted to 1.61 by 
Wolff-Kishner reduction. Finally O-demethylation with HBr gave 












1^59 R=0 (methobromfde) 1 . 54
1^60 R=0 (base)
1.61 R=H,
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AZABICYCLONONANE DISCUSSION
It has been recognised for some time that not all of the chemical 
features of morphine 1 .2 . need be retained as a prerequisite for 
analgesic potency. For example, a large number of 
6 ,7-benzomorphans 1.62. have been synthesised; many possess
significant potency and several are in clinical use as narcotic
11 12 analgesics. *
Further rationalisation of the 6,7-benzomorphan structure can still 
give rise to compounds which display analgesic action. For 
instance, 1.63 lacks many of the features of morphine yet is of
X
2 1 . 62
greater potency. 13
Modification of 1.63 by removal of the aromatic ring from its fused 
6,7 position yields the morphan system 1.64. Examples of morphans 
which have the aromatic moiety in other positions (notably the 5
O
position) yet remain potent are known for example 1 .54.
» V
1^64 R=H 




However, morphans without aromatic substituents, for example, 1.64 
and 1.65. or those with a 6,7 double bond as in 1.66. have been 
found to be inactive.
me
The presence of an aromatic ring in the morphan system has been 
demonstrated to be a necessity for analgesic activity; this is 
probably a binding requirement of the opioid receptors.
Aims and Objectives
In order to investigate the effect on analgesic activity of moving 
the aromatic ring to alternate sites in the morphan system, the 
morphan-8-one 1.46 was required. 8-Aryl derivatives should then 
easily follow, for example via Grignard reactions.
The syntheses of 5, 6 , 7, 8 and 9 functionalised morphans have been
3-7 5reported and one method was initially selected for use in this
work (scheme 1.9). However, due to difficulties associated with the
cyclisation stage using this method, an alternate route was
developed in these laboratories (scheme 1.10). Both routes will be
discussed.
The reported method of synthesis of 1.46 used an intramolecular 
cyclisation of the N-chloramine 1.72 under acidic solvolytic 
conditions. 1.46 was synthesised in 8 steps from commercially 
available 4-hydroxyphenylacetic acid.'*
Attempted Synthesis of 1.46 via Solvolysis of 1.72. (Scheme 1.9^)
5
Esterification of 4-hydroxyphenylacetic acid 1.37. as reported, in 
ethanol with I^SO^ as catalyst, gave the ethyl ester 1.38 in high 
yield.
Due to lack of high pressure facilities, the catalytic 
hydrogenation of the aromatic ring in 1.38 was accomplished with a 
rhodium catalyst at 4 atmospheres and 25°C, as an alternative to 
the original method which used a Raney nickel catalyst at 130 
atmospheres and 150°C. However, this alternate procedure did lead 
to approximately 20Z of hydrogenolysed ester 1.67. which was 
separated from the required hydroxycyclohexyl ester 1.39 by 
fractional distillation under reduced pressure.
Oxidation of the hydroxyl group in 1.39 was achieved using Jones 
reagent^ as an alternative to acidic potassium dichromate as 
originally reported^. The resulting ketone 1.40 was protected as 
the ketal 1 .68. obtained by azeotropic distillation of 1.40 with 
ethylene glycol and p_-TSA in toluene, as in the original method.
Methaminolysis of 1 .68 with methylamine in ethanol over several 
weeks at ambient temperature gave 1.70. Use of sodium methoxide as 
a catalyst as reported was discontinued as this encouraged 
hydrolysis to acid 1.69.
1^37 R=H 
1^38 R=Et















Reduction of the acetoxamide side chain of 1.70 with LAH gave amine 
1.71. The N-chloramine 1.72 was obtained quantitatively by 
treatment of 1.71 with sodium hypochlorite solution. Use of the 
reported solvolytic techniques for cyclisation of 1.72 
(trifluoroacetic acid/methanol) failed to give any cyclic products 
and resulted only in recovery of 1.71 in poor yield. Repetition of 
the reaction using trifluoroacetic acid containing traces of water 
(as suggested by the authors when consulted) gave no improvement.
This stage is elaborated in scheme 1.9.^
Synthesis of 1.46 via bromination of 1.70 and subsequent ring 
closure (scheme 1 .10).
Due to the failure of the solvolytic cyclisation of 1.72 (scheme 
1.9), the required morphan-8-one 1.46 was obtained by a different 
route developed in these laboratories (scheme 1.10). The route 
utilised the amide 1.70 from scheme 1.9 as starting material.
Bromination of 1.70 in ethylene glycol gave a mixture of the
6-bromo trans 1.73a and cis 1.73b isomers. The proportions of each 
isomer obtained was temperature dependent with 1.73b predominating 
at ambient temperature (802 @ 20°C). At 55°C, (the maximum 
temperature before other reactions interfered) the isomers were 
obtained in approximately equimolar proportions as judged by GLC 
and NMR. Only the trans isomer 1.73a could ultimately be 
cyclised (see later) and so the bromination was carried out at 
55°C in order to maximise its yield. 1♦73a was obtained pure after 
fractional crystallisation of the isomeric mixture from toluene.
NHMe
1_^ _73a R+R1=0  
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Reduction of the amide group in 1.73a with diborane in THF gave 
amine 1.74a. An aqueous solution of the hydrochloride salt of 
1 .74a cyclised on treatment with aqueous ammonia to give the 
cyclic ketal 1.75. Deprotection of 1.75 with aqueous HC1 gave 
the required morphan-8-one 1.46. The overall yield of 1.46 from 
hydroxyphenylacetic acid was approximately 21.
This low yield was largely attributable to the stereoselective 
nature of the cyclisation stage, and the consequent need to 
separate the isomeric amides 1.73a/b.
The stereochemistry of the brominated intermediates are therefore 
of interest and will now be discussed with particular reference to 
their NMR spectra.
Examination of molecular models (see scheme 1.10) showed that the 
acetoxamide side chain and bromine must be trans for the subsequent 
cyclisation to occur by the expected SN2 mechanism. The major 
product from the bromination of 1.70 i.e. 1.73b did not 
subsequently cyclise and on this basis was assigned the cis 
configuration. Conversely, 1.73a was assigned the trans 
configuration.
The observed ^H NMR spectra of the isomers of 1.73 and 1.74 
provided evidence to support these assignments and this evidence 
will now be presented.
The 400 MHz NMR spectrum of 1.73a showed the CHBr proton at 8 - 
4.15 ppm as a narrow quartet with both couplings (to Ha and Hb) 
2-3Hz (figure 1.1). This is indicative of an equatorial 
conformation for CHBr i.e., bromine axial in 1.73a. The 400 MHz "^H 
NMR spectrum of 1.73b showed the corresponding CHBr proton at 
5-4.2 but obscured, and so no coupling information was available 
(figure 1 .2).
The 60 MHz ^H NMR spectra of the amines 1.74a/b also provided 
useful data, in that although the CIIBr proton of 1.74b was again 
obscured at 8 - 4.2 (figure 1.4), the corresponding signal in 1 .74a 
occurred at 8 - 4.7, which is indicative of an equatorial proton.
Note:- 1.74a has partially cyclised, thus complicating its ^H NMR
(figure 1.3).
Also compare the chemical shift of CHBr in cis and 
trans-4-tert-butyl-l-bromocyclohexanes16 (figure 1.5).
FIGURE 1 .1
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The 13C NMR spectra of 1.73/4a and 1.73/4b were also in accord with 
these assignments (figure 1.6 and table 1 .1 ) as shown below.
TRANS
2 9 . 9
4 2 . 229 2 9 . 2
5 3 9  3 8 . 8
1 .73a
CIS
3 5 . 6
4 2 . 83 5 . 1 2 9 . 4




Note that C-l and C-5 are sterically compressed by axial bromine3"^  
in 1.73a. and therefore have higher field chemical shifts than the 
corresponding carbon atoms in 1.73b (figure 1.6). A similar 
pattern of shielding of C-l and C-5 was also observed in 1.74a 
(table 1 .1).
When a mixture of 1.74a and 1.74b were subjected to cyclisation 
conditions, yields of cyclised product 1 .75 were poor. This 
suggested an interspecies association which precluded the expected 
cyclisation of 1.74a. It was therefore necessary to separate 
1.74a and 1.74b before cyclisation was possible. This was most 
easily accomplished at the amide stage, i.e. 1.73a/l.73b. as these 
were solids which could be separated by fractional crystallisation. 
The amines 1.74a and 1.74b were liquids with similar boiling 
points. Separation by fractional crystallisation of their 
hydrochloride or oxalate salts was also attempted without success.
In an attempt to utilise the unwanted isomers 1.73/4b and so
18synthesise 1.76 the Finklestein halogen exchange process was also 
unsuccessfully attempted (scheme 1 .11).
R R
Na I /M e2CO
1 .73/4b 1 .76
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Having synthesised 2-azabicyclo [3#3,l]non-8-one 1.46. the purpose 
of the synthesis could be realised, i.e. introduction of an 
aromatic moiety at position 8 .
With this aim, 1.46 was reacted with phenyllithium in anhydrous 
ether. The alcohol 1♦77 was obtained in moderate yield after 
rigorous purification. IR studies of 1.77 revealed no shift of the 
0-H band at 3350cm”1 on dilution to 0.005M (CCl^), and no free 0-H 
was detected. This suggested an entirely intramolecularly H-bonded 
structure (scheme 1 .12).
1 . 4 6
1 . 7 7
1 . 7 8
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Acetylation of 1.77 with acetyl chloride and triethylamine in 
anhydrous ether gave the corresponding ester 1.78. The 
hydrochloride salt of 1.78 was found to be hygroscopic and could 
not be obtained pure. However, the oxalate salt was obtained pure 
and used for biological testing.
Biological Results
lf-methyl-8-acetoxy-8-phenyl-2-azabicyclo [3,3%l]nonane oxalate 1.78. 
was tested for analgesic activity using the mouse hot-plate test 
(MHP). It was found to be essentially inactive with an ED2Q of 
lOOmg/kg.
Experimental Section
Infra-red spectra were recorded on a Unicam SP1025 spectrometer.
Melting points (uncorrected) were taken on a Gallenkamp melting 
point apparatus.
13C NMR spectra were recorded on a JEOL FX90Q spectrometer 
operating at 22.5 MHz. The multiplicity of the resonances was 
obtained by either off-resonance (partial 1H coupling) spectra, or 
by INEPT (Insensitive Nuclei Enhanced by Polarisation Transfer) 
spectra in which the phase of the signal indicated the number of 
protons attached to each carbon atom.
NMR spectra were recorded using JEOL JNM-PMX 60 SI, JEOL PS100 
and JEOL GX400 spectrometers. NMR samples (as bases unless stated 
otherwise) were prepared in 5mm o.d. tubes as approximately 102 
solutions in CDCl^ (unless stated otherwise) with TMS as reference.
Mass spectra were recorded on a VG 7070E mass spectrometer 
operating at 70 eV (El).
Optical Rotations were measured on an Optical Activity Ltd AA-10 
polarimeter.
Elemental analyses were performed by Butterworths Laboratories 
Ltd., Middlesex.
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NaOH Sodium Hydroxide






Solvent was removed - denotes evaporation under reduced pressure 
using a rotary evaporator.
A  5
Ethyl 4-hydroxyphenyl acetate (1.38)
A stirred mixture of 4-hydroxyphenylacetic acid 1.37 (375 g, 2.47 
mol), EtOH (750ml) and concentrated H2S0^ (15ml) was heated under 
reflux for 3 hours, then cooled and solvent removed. The residue 
was dissolved in water (600 ml) and extracted with Et20 (5 x 75 
m l). The combined organic layers were washed with NaHCO^ solution, 
dried (MgSO^) and solvent removed to yield crude 1.38 as a yellow 
oil. Distillation under reduced pressure gave 1.38 (400g, 90Z) as 
a colourless oil, b.p. 127-8°C § 0.4 mmHg (lit5 b.p. 138°C §
0.5mmHg).
1H NMR 1.22 8 (t, J*7 Hz, 3H, CH3)
3.50 8 (s, 2H, ArCH2)
4.15 8 (q, J=7 Hz, 2H, CH2)
6.53 8 (br s, 1H, OH, exchanges with D20)
6.65 - 7.2 8 (m, 4H, ArH)
A  5
Ethyl 4-hydroxycvclohexyl acetate (1.39)
A solution of 1.38 (217g, 1.21 mol) in EtOH (500 ml) was 
hydrogenated in a Parr apparatus at 60 psi over 5Z rhodium on 
carbon (25g) for 72 hours at 20°C. The mixture was filtered 
(Celite) and solvent removed to afford a colourless oil,which 
proved to be a mixture. Distillation under reduced pressure gave 
1.39 (160g, 71Z) b.p. 115°C @ 0.4 mmHg (lit5 b.p. 115-6°C g 0.4mm 
Hg), and as a forerun, ethyl cyclohexylacetate (1.67: 45g, 22Z), 
b.p. 30-40°C g 0.4 mmHg (lit*^ b.p. 42-3°C g 0.2 mmHg), both as 
colourless oils.
1.39
IR (neat) 1740 cm”1 strong (C*0)
3450 cm"1 broad (0-H)
1H NMR 1.24 8 (t, J=7Hz, 3H, CH3 )
1.3 - 2.35 8 (m, 12 aliphatic H with br s at 1.58)
2.42 8 (s, 1H, OH, exchanges with D2O)
4.13 8 (q, J=7Hz, 2H, CH2)
(1 . 6 7 ^  NMR as 1.39 excluding 0-H signal)
A  5Ethyl 4-oxocyclohexyl acetate (1.40)
To a stirred solution of 1.39 (lOOg, 0.54 mol) in Me2CO (400 ml) 
was slowly added Jones reagent15 (made from CrO^ 80.lg, H2SO^ 69ml, 
and water 210 ml) keeping the temperature of the reaction mixture 
less than 20°C with external cooling. The mixture was stirred for 
a further hour, then the bulk of the Me2C0 removed under reduced 
pressure and the residual solution extracted with CHC13 (5 x 200 
ml). Drying (MgSO^) and removal of solvent gave a yellow oil. 
Distillation under reduced pressure gave 1.40. (89g, 902) as a 
colourless oil, b.p. 112-5°C § 1.0 mmHg (lit5 b.p. 100-115°C g 1.0 
mmHg).
IR (neat) 1730 cm”1 strong (C=0)
1H NMR 1.26 8 (t, J-7Hz, 3H, CH3)
1.5 - 2.5 8 (m, 11 aliphatic H)
4.16 8 (q, J=7Hz, 2H, CH2)
a  A, 5
Ethyl 1,4-dioxaspiro r4,51 decane-8-acetate (1.68)
A mixture of 1.40 (lOOg, 0.54 mol), ethylene glycol (55g, 0.9 mol) 
and p-TSA (2g) in toluene (400 ml) was azeotropically distilled in 
a Dean-Stark apparatus for 2 hours. The cooled mixture was washed 
with dilute NaHCO^ solution (3 x 50 ml), brine (3 x 50 ml) and 
dried (Na2S0^). Removal of solvent gave a yellow oil which was 
distilled under reduced pressure to give 1.68. (llOg, 892) as a 
colourless oil, b.p. 112-4 6 0.5mmHg, (lit** b.p. 95-8°C § 0.3mmHg).
IR (neat) 1730 cm"1 strong (C=0)
1H NMR 1.25 8 (t, J=7Hz, 3H, CH3)
1.5 - 2.4 8 (m, 11 aliphatic H)
3.9 8 (s, 4H, 0CH2CH20)
4.1 8 (q, 2H, CH2CH3)
A  A  5
N-Methyl 1.4-dioxaspiro T4.51 decane-8-acetoxamide (1.70)
Methylamine (30g, 1 mol) was condensed into a chilled solution of 
1 .68 (lOOg, 0.44 mol) in EtOH (500 ml), stirred at 20°C for 5 weeks
with addition of further methylamine as necessary. At the end of
this time excess methylamine and solvent were removed to give a 
solid residue. This crystallised from cyclohexane to give 1.70. 
(72.5g, 782) as white flakes, m.p. 109 - 110°C, (lit5 m.p. 120°C).
IR (CDC13) 1645 cm"1 strong (C=0)
3320 cm"1 (N-H)
1H NMR 1.2 - 2.2 8 (m, 11 aliphatic H)
2.75 8 (d, J=4.5Hz, 3H, NCH3 )
3.91 8 (s, AH, 2 x CH2 )
6.3 8 (br s 1H, NH, exchanges with D20)
13C NMR See table 1.1
8- (N-Methvlaminoethyl)-l.A-dioxaspiro rA,51 decane (1.71) 5
A solution of 1.70 (25g, 0.12 mol) in anhydrous THF (150 ml) was 
added slowly to a mixture of LAH (lOg, 0.25 mol) in anhydrous THF 
(100 ml), and the mixture refluxed for 16 hours. The mixture was 
cooled in an ice bath, then 2N NaOH (10 ml) was cautiously added 
dropwise and the suspension stirred a further 1 hour. Filtration 
and washing of the cake with CH2C12 (200 ml), drying (MgSO^), and 
removal of solvent gave a residue which was distilled under reduced 
pressure* to give 1.71. (18.Ag, 792) as a colourless oil, b.p. 98°C 
g 0.3mmHg, (lit5 9A-98°C g 0.3mmHg).
*Tends to polymerise especially at lesser vacuum.
^H NMR 1.1 - 1.9 8 (m, 11 aliphatic H)
2.A5 8 (s, 3H, NCH3)
2.61 8 (t, J=8Hz, 2H, NCH2 )
3.95 8 (s, AH, 0CH2 >
13C NMR See table 1.1
A  A  5
8- (N-Chloro-N-methylaminoethyl)-1.4-dioxaspiro TA.51 decane Cl.72)
A mixture of 1.72 (l.Og, 0.005 mol), CH2C12 (12 ml) and 1M sodium 
hypochlorite solution (12 ml) was vigorously stirred for 90 minutes 
at 20°C, in the absence of light. The aqueous layer was separated 
and extracted with CH2C12 (3 x 10 ml). The combined organic layers 
were dried (Na2S0^) and solvent removed to yield 1.72. (l.lg, 942) 
as a pale yellow oil. This was used for the subsequent attempted 
cyclisation without further purification.
1H NMR 1.1 - 1.9 8 (m, 11 aliphatic H)
2.94 8 (t, J-8Hz, 2H, NCH2 )
2.96 8 (s, 3H, NCH3)
3.95 8 (2, 4H, 0CH2CH20)
13C NMR See table 1.1
a  a
6-Bromo-N-methyl-l.4-dioxaspiro T4«51 decane-8-acetoxamide (1.73)
Bromine (15.1g, 0.094 mol) was added slowly dropwise to a solution 
of 1.70 (20g, 0.094 mol) in ethylene glycol (400 ml) maintained at 
55°C. The mixture was stirred for a further hour then cooled, 
basified with 2N K£C®3 s°luti°n an^ extracted with toluene (5 x 
100 ml). Drying (Na2S0^) and removal of solvent gave an 
approximately equimolar mixture of 1.73a/b as a pale yellow solid, 
(17g, 622). Repeated crystallisation from toluene gave 1.73b 
(4.5g, 162) as white needles, m.p. 152-3°C.
EIHS m/z 292 (M+)
r; o
1H NMR 1.3 - 2.5 6 (m, 9 aliphatic H)
2.75 6 (d, J-4.5 Hz. 3H, NCH3)
3.9 - 4.25 8 (m, 4H, 0CH2CH20)
4.15 - 4.25 6 (1H. obscured, CHBr)
6.1 B (br s, 1H, NH, exchanges with D20)
13C NMR See table 1.1
Analysis See table 1.3
Further crystallisation of the combined residues from toluene gave 
1.73a (3.9g, 142) as a white crystalline solid, m.p. 127.5-8.5°C.
EIMS m/z 292 (M+)
1.2 - 2.6 B (m, 9 aliphatic H)
2.75 B (d, J=4.5Hz, 3H, NCH3)
3.95 - 4.05 B (m, 4H 0CH2CH20)
4.15 B (AB q, J=2.5Hz, CHBr)
6.3 B (br s, 1H NH, exchanges with D20)
13C NMR See table 1.1
Analysis See table 1.3
A A
6-Bromo-8-(N-methylaminoethvl)-1.4-dioxaspiro T4»51 decane (1.74)
To a stirred solution of 1.73a * (l.Og, 0.0034 mol) in anhydrous 
THF (50 ml), at 0°C, under a nitrogen atmosphere, was added (via 
syringe), 15 ml of 1M diborane in THF. The resulting solution was 
refluxed for 5 days, then cooled. Acetic acid (50 ml) was added 
and the mixture stirred at 20°C for 30 minutes. Solvent was 
removed, the residue basified with 2N Na2C03, and extracted with 
EtOAc (3 x 75 ml). The combined organic layers were dried (MgSO^) 
and solvent removed to give a yellow oil. Distillation under 
reduced pressure in a Kugel Rohr apparatus gave 1 .74a (0.6g, 63Z) 
as a colourless oil, b.p. 125°C @ 0.05 mmHg.
1H NMR 1.1 - 2.7 8 (m, 11 aliphatic H)
2.3 8 (s, 3H, NCH3)
3.75 8 (s, 4H, 0CH2CH20)
3.5 8 (br s, 1H, NH, exchanges with D20)
4.7 8 (brd, J=4Hz, CHBr)
13C NMR See table 1.1
* 1•73b was similarly reduced to 1.74b. which also had b.p. 125°C 6 
0.05 mmHg. (Yield was also comparable to that of 1.74a).
1.74b
1H NMR 1.1 - 2.3 8 (m, 9 aliphatic H)
2.42 8 (s, 3H, NCH3)
2.58 8 (t, J=7Hz, 2H, NCH2)
3.9 - 4.25 8 (m, 4H, 0CH2CH20)
4.15 8 (1H, obscured, CHBr)
13±0C NMR See table 1.1
\ 61
2-Methvl-8-oxo-2-azabicyclor3.3.11nonane ethylene ketal 
(1-75) 5
To a solution of the hydrochloride salt of 1 .74a* (7.0g, 0.022 mol) 
in water (25 ml) at 0-5°C, was added dropwise, concentrated aqueous 
ammonia (2.5 ml) over 15 minutes. The solution was stirred for a 
further hour then extracted with CHClg (3 x 25 ml). The combined 
organic layers were dried (MgSO^) and solvent removed to give a 
pale yellow oil. Distillation under reduced pressure gave 1.75. 
(3.7g, 84Z) as a colourless oil, b.p. 72°C § 0.1 mmHg.
EIMS m/z 197 (M+)
NMR 1.2 - 2.6 5 (m, 11 aliphatic H)
2.27 8 (s, 3H, NCH3)
3.05 8 (t, 1H, NCH )
3.9 8 (s, 4H, 0CH2CH20)
13C NMR See table 1.2
* The hydrochloride salt of 1 .74b consistently failed to give any 
cyclised products under these conditions. An isomeric mixture of 
1.74a/b also failed to yield any significant 1.75 (see discussion).
2-Methyl-2-azabicyclo f3>3>llnon-8-one (1.46)
A solution of 1.75 (3.7g, 0.019 mol) in 30Z HC1 (25 ml) was stirred 
at 20°C for 16 hours, then washed with Et20 (3 x 25 ml), basified 
with Na2C03 and extracted with CHCl^ (3 x 25 ml). The combined 
CHClj extracts were dried (MgSO^) and solvent removed to give a 
residual oil. Distillation under reduced pressure gave 1.46.
(1.75g, 61Z) as a colourless oil, b.p. 72°C § 0.1 mmHg. The 
hydrochloride and oxalate salts were found to be hygroscopic and 
could not be obtained pure.
EIMS m/z 153 (M+)
IR (neat) 1715 cm"1 strong (C*0)
NMR 1.3 - 2.7 8 (m, 11 aliphatic H)
2.22 8 (s, 3H, NCH3)
3.0 8 (t, J=7.5Hz, 1H, CHN)
13C NMR See table 1.2
Analysis See table 1.3
8-Hydroxy-2-methyl-8-pheny1-2-azabicyclor3»3,11nonane (1.77)
To a stirred solution of phenyllithium in anhydrous Et20 (100 ml) 
made from bromobenzene (2.56g, 0.0164 mol) and lithium (0.23g, 
0.0328 mol) and left to react for 1 hour, was slowly added a 
solution of 1.46 (1.25g, 0.0082 mol) in anhydrous Et20 (50 ml).
The mixture was stirred at 20°C for 1 hour then excess lithium 
removed and the solution acidified with 2N HC1. The aqueous layer 
was separated and washed with Et20 (3 x 50 ml) then basified 
(l^COg) and extracted with Et20 (3 x 100 ml). The combined 
ethereal extracts were dried (MgSO^) and solvent removed to give a 
viscous orange oil (1.35g). This was chromatographed on silica gel 
using CHClg as eluant to give 1.77. (0.55g, 291) as a viscous 
yellow oil which solidified on standing, m.p. 35-40°C.
IR (neat) 3300 cm"1 (0-H)
No shift of this band was observed on progressive dilution with 
carbon tetrachloride (to 0.005M) which indicated an entirely 
intramolecularlv H-bonded structure (scheme 1.12).
1H NMR 1.2 - 2.6 5 (m, 11 aliphatic H)
2.32 8 (s, 3H, NCH3)
3.1 - 2.6 8 (m, 1H, NCH)
6.4 8 (br s, 1H, OH, exchanges with D2O)
6.7 - 7.5 8 (m, 5H, ArH)
13 NMR See table 1.2
6 /i
8-Acetoxy-2-methyl-8-phenyl-2-azabicyclo T3.3>11nonane (1.78)
To a solution of 1.77 (0.3g, 0.0013 mol) and freshly distilled 
triethylamine (0.5gt 0.005 mol) in anhydrous 'Stfl (10 ml) was 
slowly added a solution of freshly distilled acetyl chloride (0.4g,
0.005 mol) in anhydrous Et20 (5 ml) and the mixture stirred at 20°C 
for 30 minutes. The precipitated solid was filtered, washed with 
anhydrous Et20 (15 ml) and the filtrate evaporated to yield 1.78.
(0.025g, 71Z) as a viscous yellow oil. The oxalate salt 
crystallised from EtOH as fine needles (0.21g, 45Z), m.p. 163-4°C.
EIMS m/z 273 (M+)
NMR 0.8 - 3.5 8 (m, 12 aliphatic H)
1.97 8 (s, 3H, C0CH3)
2.25 8 (s, 3H, NCH3)
7.1 - 7.5 8 (m, 5H, ArH)
13C NMR See table 1.2
Analysis See table 1.3
TABLE 1 .1 ___ 13C NMR DATA ON SOME 8■ SUBSTITUTED 1 ,4-D IO XASPIRO [4,5]DECANES
Compound 8 C1 C2 C6 C b 3 C5 C4 Cot cp Dioxolane » - ch3
1 .70 34 .0 30 .2 30 .2 34.4 34.4 108.7 173.1 43.3 64 .2 26 .1
1.71 34.6 30.3 30.3 34.3 C 34.3 109.2 50.2 3 4 . 6C 64.2 36.6
1 .72 34.0 30 .2 30 .2 34.5 34.5 108.9 64.4 34.5 64 .2 52.8
1.73a 29.9 38.8 29.2 53.9 29.0 108.0 172.4 42 .2 65 .0  65.3 26.3
1.73b 33.6 41.8 29.4 56.7 35 .1 107.6 172.1 42 .2 65 .7 .  66 .1 26.3
1 .74a 29.4 42.0 29.9 54.3 2.0 108.0 49.8 39 .0 64 .7 ,  64 .9 36.6
1.74b 35.5 42.2 29.6 57.4 35.3 107.9 49.7 36 .1 65 .7 ,  66 .1 36 .5
a : Free base in CDCl^ with TMS as reference 
b : C3, brominated where appropriate 
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1.75 64.5 30.2 26.9b , 28.5b , 29.7b , 32.6b 36.8 108.9 39.8 63.8, 64.5 (Dioxolane)
1.46 63.7 30.3 26.7b , 29.7b , 35.8b , 36.6b 41.6 212.0 40.4
1.77 66.0 30.2 26.9b , 29.lb , 36.0b , 38.0b 37.4 73.0 40.4 124.4, 126.2, 128.0, 148.8 
(Aromatics)















Analytical Data Table 1.3
Compound Formula
C H N
1.73a C11H18N03Br Calc 45.25 6.21 4.80
Found 45.20 6.16 4.64
1.73b C1;LH18N03Br Calc 45.25 6.21 4.80
Found 45.19 6.06 4.75
1.46 C9H15NO Calc 70.55 9.87 9.14
Found 69.55 10.06 8.97
1.78 C17H24N02 .HC204 Calc 62.80 6.93 3.85
Found 62.73 6.99 3.98
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CHAPTER TWO 70
QUINUCLIDINE INTRODUCTION
Quinuclidine is the bicyclic amine 1-azabicyclo[2,2*2]octane 2.1.
It is found as an important structural fragment of several
alkaloids of the Cinchona group, notably the antimalarial quinine










Several physiologically active synthetic quinuclidine derivatives
3-7are in the literature and their neurotropic activities have 
been extensively investigated.^
For example, the diquatemary salts dioquin 2.5 and dicoline 2.6 




DI COL INE 
DIMECOL INE
The neurotropic activity of these aminoalkyl esters of
quinuclidine-2-carboxylic acid generally perists when the
quinuclidine moiety is replaced by the monocyclic piperidine
system. However, this is not always the case. For example, in
compounds of the type 2 .8 . replacement of the quinuclidine moiety
1 2by acyclic amines leads to loss of neurotropic activity. ’
‘COoCHoNRoRoR,
Me
2j_5 R1=H R2=R3=Et R4=Me 





The most neurotropically active synthetic quinuclidine is
Q
qualidyl 2.9. in which two 3-benzylquinucidine molecules are
linked symmetrically by an alkyl chain of 6 carbons through the 
nitrogen atoms.
Some simple esters of 3-hydroxyquinuclidine, for example 
aceclidine 2 .10. also possess neurotropic activity in that they 
cause the relaxation of smooth muscle tissue. These compounds are 
thought to act as agonists at acetylcholine muscarinic receptors. 
The chemical relationship between 2.10 and acetylcholine (2.11) is 
shown below.
2 C I - 2 . 9
+ +
7-7
Acedidine induces contraction of the pupil of the eye and is used




Quinuclidine has a rigid, fixed structure in which both piperidine 
rings are held in ’boat’ conformations.
As a consequence, the lone pair of electrons on the nitrogen atom 
are virtually unscreened by the adjacent C-H bonds. This endows 
the quinuclidine molecule with some interesting chemical (and 
hence biological) features.
For instance, its reactivity with alkyl halides is much greater 
than that of other simple tertiary aliphatic amines. Quinuclidine 
reacts with methyl iodide 50 times faster and with isopropyl 
iodide 700 times faster, than does triethylamine. As a result of 
this, functionalised quinuclidine derivatives may often have 
unpredicted chemical properties.
One important example of this is 2-quinuclidinone 2.12 which 
behaves as an amino ketone rather than as an amide, as might 
otherwise be expected.
o
This property is due to the unfavourable orientation of the
nitrogen £  orbitals with respect to the carbonyl pi electrons.
+ ~
Conjugation of the type N-C^O <-> N=C-0, normal in conventional 
amides, is impossible in 2-quinuclidones.
2-Quinuclidones are therefore highly basic compared to other 
amides and are readily protonated. The hydrogen atoms on the 
carbon atom adjacent to the carbonyl group are acidic, being 
readily removed by bases, and will also exchange with D2O. The 
carbonyl group will also undergo nucleophilic substitution 
reactions (such as oxime formation), in contrast to carbonyl 
groups in conventional amides.
Synthesis
There are several methods which have been used for the synthesis 
of the quinuclidine ring system; these often utilise 
intramolecular alkylation of haloalkylpiperidine derivatives which 
are usually obtained by reduction of the corresponding pyridine 
(scheme 2 .1).
SCHEME 2 .1
The first synthetic quinuclidine derivative, 3-ethylquinuclidine
Q
2.17. was prepared in 1904 by Koenigs , who utilised this 
technique for the intramolecular alkylation of 
4-(2-iodoethyl)-3-ethylpiperidine 2.16 to achieve quinuclidine 
ring closure (scheme 2 .1a).
Starting from 3-ethyl-4-methylpyridine (2.13). condensation with 
formaldehyde gave the alcohol 2.14. which was isolated in low 
yield and subsequently reduced to the piperidine derivative 2.15 
using sodium in ethanol. Reaction with HI gave the 4-(iodoethyl) 
derivative 2.16. which cyclised under the influence of base to 
give 3-ethylquinuclidine 2.17.
The major disadvantage of Koenigs* synthesis was the extremely low 
yield (1-22) of 2.14. However, later workers were able to improve 
the yield at this stage by the use of paraformaldehyde and higher 
temperatures.
Similar syntheses were used by later workers to prepare the 
4-cyano, 4-bromo and 4-hydroxyquinuclidine derivatives. In these 
cases, tertiary rather than secondary amines (piperdines) were 
employed and the appropriate alkyl halide was eliminated from the 
quaternary salt after cyclisation, by heating under vacuum. For 
example, in the synthesis of 4-cyanoquinuclidine, 2.21 in scheme
2.2 4-cyano-l-methylpiperidine 2.18 was used as starting 
material. Reaction with dichloroethane gave the haloalky/ 
derivative 2.19. Alkaline intramolecular cyclisation gave the 
quaternary salt 2 .20. which eliminated methyl chloride when heated 
to 270°C under vacuum and gave 4-cyanoquinuclidine 2.21.
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SCHEME 2 .2  11
In a similar manner to that shown in scheme 2.2, the use of
4-(haloacetyl)-4-substituted-l-benzylpiperidines as starting
materials led to 3-oxo-A-substituted quinuclidines. Examples of





SCHEME 2 .3  12
In the synthesis of the Cinchona alkaloids a different approach
was sometimes required, to avoid the difficulty of halogenation of
the oxoalkyl side chain when a vinyl group was also present. This
modification involved the synthesis of the N-bromo rather than the
appropriate C-bromo intermediate prior to cyclisation. The
13synthesis of quinine, 2.2 shown in scheme 2 .A , is used to
illustrate the method. N-Bromination of the starting material
2.22 was achieved with sodium hypobromite. 2.23 was cyclised to
ketone 2.2A with alkoxide. The quinine skeleton was obtained by
subsequent reduction of 2.2A. A number of other Cinchona






2^24 R+R1 =0 
2^2 R=H R1=0H
(Quinine skeleton)
SCHEME 2 .4  13
In the 1940s a different approach to the synthesis of quinuclidine 
derivatives was developed by P r e l o g . T h e r e  were two 
variations : 1) the reaction of suitable tribromoalkanes with 
ammonia under pressure and 2 ) the double intramolecular alkylation 




B r - H 2N'
base
SCHBME_2^_5
Although these two methods could be used to prepare simple 2 , 3 
and 4-alkylated quinuclidine derivatives, they were not
universally applicable. For example, they failed when used in an
attempted preparation of the quinine analogue 2.25 (scheme 2.5a 1^).
On occasion, either Koenig’s or Prelog’s method may be used to
synthesise a given quinuclidine derivative. This is illustrated 
for the synthesis of the important intermediate quinuclidine 
2-carboxylic acid (2.26 in schemes 2.6 and 2.7).
SCHEME 2 . 5 a
Using Koenie* s method (scheme 2.6 the starting material, 
4-methylpyridine 2.27 was oxidised to the 4-formyl derivative 
2.28. Condensation of 2.28 with malonic ester gave the 
4-(dicarboxyvinyl)pyridine 2.29. The corresponding fully reduced 
piperdine derivative 2.30 was obtained by hydrogenation of 2.29 
over a platinum catalyst. Bromination of 2.30. followed by the 
usual alkaline intramolecular ring closure gave the
2-(diethoxycarboxyl)quinuclidine 2.32. Hydrolysis and partial 
decarboxylation gave the required quinuclidine-2-carboxylic acid 
2.26.
Prelog’s original synthesis of 2.26 in 1937 started with
18dichloroethyl ether 2.33 (scheme 2.7 ). Reaction with malonic
ester gave the diester 2.34. Hydrolysis, partial decarboxylation 
and re-esterification of the remaining carboxyl group in 2.35 gave 
mono-ester 2.36. Reduction of 2.36 with sodium in ethanol gave 
the alcohol 2.37. which was converted to the corresponding bromide 
2.38. This reacted with malonic ester to give 2.39. Hydrolysis 
and partial decarboxylation gave the mono-acid 2♦40. Opening of 
the pyran ring of 2.40 with HBr under pressure gave 2.41 which was 
then brominated a to the carboxyl group. The resulting 
tribrominated derivative 2.42 cyclised on treatment with ammonia 
under pressure to give quinuclidine-2-carboxylic acid 2.26. The 
overall yield was 42.
Quinuclidine-2-carboxylic acid is an extremely useful starting 
material for the synthesis of many other 2-substituted 
quinuclidine derivatives. Some of these possible transformations 





2^29 R=CHCH(C02Et ) 2
CHoR
2^30 R=CH(C02E t ) 2 
2^31 R=0Br(CO2E t ) 2
R
2^32 R=R1 =C02Et
SCHEME 2 .6 17
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SCHEME 2 .8  2
Another versatile quinuclidine derivative which has been widely 
used for the preparation of many 3 and 2,3 substituted 
quinuclidines is 3-quinuclidone 2.44. first prepared by Clemo 
and Metcalfe in 1937. ^
Starting from ethyl isonipecotinate (2.45 in scheme 2.9), reaction 
with ethyl chloroacetate gave the diester 2.46. Cyclisation of 
2.46 with potassium in toluene, followed by saponification of the 
resulting quinuclidine ester 2.47 and decarboxylation of the 
resulting acid 2.48 led to 3-quinuclidone 2.44. Other workers 
subsequently modified and improved the synthesis. For example, 
potassium tert-butoxide could be substituted for metallic 
potassium at the cyclisation stage to give a greatly improved 
yield. 20
Some of the many 3 substituted and 2,3 disubstituted quinuclidine 
derivatives which may be prepared from 3-quinuclidone are 
illustrated in scheme 2 .10.
Some of these transformations were utilised for the preparation of 
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SCHEME 2 . 1 0
QUINUCLIDINE DISCUSSION
4-Arylpiperidine based narcotic analgesics are an important class 
of drugs for the treatment of chronic pain. Pethidine 2.49. its
3-methyl reversed ester derivatives (prodines) 2.50 and fentanyl 








2 . 5 0
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Several 3-arylpiperidines have been reported, for example 
^-pethidine 2.52 is approximately one half as active as pethidine 
Others in this class also retain analgesic properties, albeit at 







2 . 5 2
N*-CH2CH2Ph
Ph Me
2 . 5 3
The single isomeric form of the 3-arylpiperidine derivative
tentatively assigned the configuration represented by 2.53 is one
exception, showing analgesic activity several times that of
21pethidine in rodent tests.
Fentanyl 2.51 is a 4-anilinopiperidine analogue of pethidine and 
is a highly potent, short acting analgesic which has been used in
structure activity relationships of fentanyl derivatives largely 
follow those in the pethidine and prodine series. Thus 
cis-3-methvlfentanvl. 2.54. is 8 times more active than fentanyl
Constrained analogues of piperidine-based analgesics have also 
been reported and certain of these have proved potent in rodent 
tests. For example, the two 3-azabicyclo [3,3,l]nonane derivatives 
2.55 - 2.57 exhibit a higher level of analgesic potency than
pethidine itself and may be considered as a class of
26
3,5-trimethylene bridged 4-arylpiperidines.
Quinuclidines are a further class of sterically constrained 
piperidine derivatives and although many quinuclidines exhibit 
various neurotropic actions, few have been examined for analgesic 
activity.
23clinical practice over the last 20 years. The stereochemical
itself.2*’25
CH2CH2Ph H
2 . 5 4
2 . 5 7  R=COEt
2 . 5 6  R=Et
OR
In 1957, a series of 4-phenyl-3-ac^loxyquinuclidines of the type
122.58 were examined but few analgesic properties were found.
Ph
OCOR
2^44 2 . 5 8
Quinuclidine analogues of prodine and fentanyl should be readily 
accessible via 3-quinuclidone 2.44. Reaction of 2.44 with 
Grignard or similar reagents should lead to 3-arylprodine 
analogues of the type 2 .59.
Ph 
PhMgX
2 44  *- - - -  (R C 0)20
2 ^ 5 9
Similarly, quinuclidine analogues of fentanyl such as 2.60 should 
be accessible by condensation of 2.44 with aromatic amines.




Variation of the N-substituent plays an important role in the
determination of the type and magnitude of analgesic action in all
classes of narcotic analgesics. Typical examples in morphinoid
systems are N-alkyl and N-cyclopropylmethyl (CPM) which confer
antagonist properties on the derivative, and N-phenethyl, which
tends to increase agonist activity. In the prodine and other
piperidine based classes of narcotic analgesics, N-alkyl and N-CPM
derivatives generally behave as agonists and show few antagonist 
27properties , whilst the N-phenethyl substituent is important to 
the high potency of fentanyl.
Due to the tertiary nitrogen atom in the quinuclidine system, it 
is not possible to directly introduce substituents on nitrogen 
without quatemisation. However, 2-benzyl derivatives are 
accessible via condensation of 2.44 with benzaldehyde 
(Claisen-Schmidt), followed by reduction of the benzylidene double
4
bond (scheme 2 .11).
2 . 4 4
2 . 5 4
2 . 5 5
SCHEME 2 . 11  4
The 2-benzylquinuclidines accessible from 2.55 by Grignard 
reactions or by condensation with aromatic amines might then be 
considered as constrained N-phenethyl analogues of their 
piperidone counterparts (figure 2 .1).
In the present work, several derivatives of 2-benzylquinuclidine 
have been prepared in the analogues of the prodine and fentanyl 
series.
Chemistry
Quinuclidine Analogues of Prodine (Scheme 2.12)
Reaction of 3-quinuclidone with phenylmagnesium bromide in 
anhydrous THF gave the alcohol 2♦61. Subsequent treatment with 
acetic and propionic anhydride gave the esters 2.62 and 2.63 
respectively (scheme 2 .12 )^
FIGURE 2 .1
95
2 ^ 4 4
( e x  A L D R I C H  C H E M  C O .  )
2-Benzylquinuclidine Analogues of Prodine (Scheme 2.13)
Firstly, reaction of 3-quinuclidone 2.44 with benzaldehyde in 
the presence of base gave 2-benzylidene-3-quinuclidone 2.54
A
(scheme 2.11 ). Reduction of the double bond with H2 over Adams
28catalyst gave 2-benzyl-3-quinuclidone 2.55♦ Compound 2.55
reacted with an excess of phenyllithium in anhydrous ether to give 
2-benzyl-3-hydroxy-3-phenylquinuclidine 2.64. Attempts to react
2.64 directly with acetyl chloride or acetic anhydride led to 
appreciable dehydration and poor conversion to the required ester 
2.65. Substantially improved conversion to 2.65 was initially 
achieved by in situ decomposition of the organolithium complex of
2.64 directly with acetic anhydride. After ’normal* work up, a
mixture of unreacted alcohol 2.64. ester 2.65 and
2-benzyl-3-phenyl-^ 2,3-quinuclidene 2.66 was obtained in an
approximate ratio of 2 : 3 : 1 as measured by GLC analysis (area
2). Chromatography of this mixture on silica gel gave pure 2 .66
in low yield, plus a further mixture which was converted to the
oxalate salt. Crystallisation from acetone and subsequent
liberation of the free base gave pure ester 2.65. This was a
13single isomer as judged by C NMR spectroscopy (figure 2.2). 
Examination of molecular models showed the configuration with 
aromatic substituents trans (2.65a) to be sterically favoured 
(figure 2.3) and thus to be the most likely product.
2 . 6 42 . 5 5
2 . 6 5 2.66
SCHEME 2 . 1 3
FJGURE_2^2
13 C 2 2 . 5  MHz MVR 
SPECTRUM OF 2^65  
(C D C I3 so I v e n t , 
TMS r e f . )
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Quinuclidine Analogues of Fentanyl (Scheme 2.14)
Condensation of 3-quinuclidone 2.44 with aniline in toluene using 
zinc chloride as catalyst, gave the anil 2.67. This was shown to 
be an approximately equimolar mixture of cis and trans isomers by 
13C NMR (figure 2.4). Reduction of 2.67 with LAH in THF gave the 
amine 2.68. Heating with the appropriate anhydride gave the 
N-acetoxy and N-propionoxy amides 2.69 and 2.70 respectively.
Reduction of 2.70 with LAH gave the N-propyl derivative 2.71.
2-Benzylquinuclidine Analogues of Fentanyl (Scheme 2.15)
Condensation of 2-benzyl-3-quinuclidone 2.55 with aniline in 
toluene as before gave the anil 2_.7J2. In contrast to the
unsubstituted anil 2.67. 2.72 was shown to be a single isomer by
13C NMR (figure 2.5). Steric interference of the 2 aromatic rings 
probably precluded the formation of isomer 2 .72b (figure 2 .6) and 
also explained the extended reaction time (6 days) and poor yield 
of the condensation (see experimental section).
1 0 1
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FIGURE 2 .4
13 C 2 2 . 5  MHz MVF 
SPECTRUM OF 2 . 6 7
(C D C I3 s o l v e n t  





2 . 7 22 . 5 5
2 . 7 3 2 . 7 4
SCHEME 2 . 1 5
FJGURE_2^5
13 C 2 2 . 5  MHz NMR 
SPECTRUM OF 2 / 7 2  
(C D C I3 s o l v e n t , 







Reduction of 2.72 with LAH in THF gave the amine 2.73.
Examination of molecular models (figure 2.7) showed the 
configuration with aromatic substituents cis see (2.73b) to be 
unfavourable due to serious interference of the aromatic rings. 
Further crystallisation of the mother liquors and examination of 
further crops of 2.73 by NMR showed no evidence for significant 
formation of other isomers.
Reaction of 2.73 with propionic anhydride gave the ester 2.74. the
13
C NMR spectrum of which is shown in figure 2.8. This indicated 
a single isomer as expected.
FIGURE 2 .7
FIGURE 2 . 8
13 C 2 2 .5  MHz MVR 
SPECTRUM OF 2 .7 4  
(C D C I3 s o lv e n t ,  
TMS r e f . )
TMS







The two 3-arylprodine analogues 2.62. 2.63 and the constrained 
N-phenethyl-3-arylprodine analogue 2.65 were inactive at up to 
doses of 50, 50 and 20 mg/kg respectively in the mouse hot plate 
test (MHP) (table 2.1). Of the fentanyl analogues, all three of 
the quinuclidines without the 2-benzyl moiety (2.69. 2.70 and 2.71) 
were also inactive at up to doses of 100, 50 and 100 mg/kg 
respectively. However, the constrained N-phenethyl analogue 2.74 
showed a level of analgesic potency of 9.3 mg/kg which is 
approximately one-tenth that of both morphine and (racemic) 
a-prodine (2.50) (table 2.1).
This result suggests a reasonable accomodation of fit 
with the opioid receptors and indicates that appropriately 
substituted quinuclidines may be worthy of further investigation 
as potential analgesic agents.
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TABLE_2^1 
ANALGESIC A C T IV IT IE S  ON SOME 2 , 2 ,3  & 2 , 3 ,3 
SUBSTITUTED QUINUCLIDINES
Compounda R R1 r2 MHPb
2.62 Ph OCOMe H IAC (50)
2.63 Ph OCOEt H IAC (50)
2.65 Ph OCOMe CH2Ph IAC (20)
2.69
NPh
COMe H H IAC (100)
2.70
NPh
COEt H H IAC (50)
2.71d
NPh
n-Pr H H IAC (100)
*3-r»*CM
NPh
COEt H CH2Ph 9.3(6.3-13.5)
morphine sulphate 1.2
a-prodine (a-2.50) 0.85
KEY FOR TABLE 2.1
a : Compounds tested as hydrochloride salts in water 
b : Mouse hot plate (^50 mg/kg) 
c : IA=Inactive at dose level indicated 
d : Tested as oxalate salt
Experimental Section
Infra-red spectra were recorded on a Unicam SP1025 spectrometer.
Melting points (uncorrected) were taken on a Gallenkamp melting 
point apparatus.
13C NMR spectra were recorded on a JEOL FX90Q spectrometer 
operating at 22.5 MHz. The multiplicity of the resonances was 
obtained by either off-resonance (partial coupling) spectra, or 
by INEPT (Insensitive Nuclei Enhanced by Polarisation Transfer) 
spectra in which the phase of the signal indicated the number of 
protons attached to each carbon atom.
NMR spectra were recorded using JEOL JNM-PMX 60 SI, JEOL PS100 
and JEOL GX400 spectrometers. NMR samples (as bases unless stated 
otherwise) were prepared in 5mm o.d. tubes as approximately 102 
solutions in CDCl^ (unless stated otherwise) with TMS as reference.
Mass spectra were recorded on a VG 7070E mass spectrometer 
operating at 70 eV (El).
Optical Rotations were measured on an Optical Activity Ltd AA-10 
polarimeter.
Elemental analyses were performed by Butterworths Laboratories 
Ltd., Middlesex.













MgS04 Magnesium Sulphate (anhydrous)
NaOH Sodium Hydroxide






Solvent was removed - denotes evaporation under reduced pressure 
using a rotary evaporator.
2-Benzylidene-3-quinuclidone (2.54) ^
A mixture of 2.44 (28g, 0.22 mol), benzaldehyde (27.5g, 0.22 mol),
NaOH (0.2g) and EtOH (50 ml) were refluxed for 2 hours. Cooling
and removal of the bulk of solvent gave a crude residue, which,
after washing with H20 and cold EtOH was recrystallised from EtOH
L
to give 2.54 (34.3g, 912) as yellow needles, m.p. 134°C, (lit 
m.p. 130-2°C).






13C NMR See table 2.2
2-Benzvl-3-quinuclidone (2.55)
A solution of 2.54 (10.65g, 0.05 mol) in glacial acetic acid (125 
ml) was hydrogenated at atmospheric pressure and room temperature
for 48 hours over Adams catalyst (0.2 g), after which time
approximately 1 molar equivalent of hydrogen had been taken up. 
Filtration (Celite) and removal of solvent gave a crude residue, 
which was basified with 2N NaOH and extracted with Et20 (3 x 50
8 (m, 4H, 2 x CH2)
8 (t, J=2.5 Hz, 1H, 4H)
8 (m, 4H, 2 x NCH2 )
8 (s, 1H, C=CH)
8 (m, 3H, 3 x Ar-H)
8 (m, 2H, 2 x Ar-H)
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ml). Drying (Na2S0^) and removal of solvent gave a colourless 
solid which crystallised from petroleum ether (60 - 80°) to give
2.55 (7.25g, 68Z) as white granules, m.p. 76-77°C. The 
hydrochloride salt crystallised from EtOAc - EtOH as colourless 
needles, m.p. 270°C, (lit 28 m.p. 270 - 272°C).
IR (CHC13) 1725 cm-1 (C = 0 )
1H NMR 1.8 - 2.1 8 (m, 4H, 2 x CH2)
2.4 - 2.5 8 (m, 1H, CaH)
2.6 - 3.0 8 (m, 7H, 2 x NCH2, Ar CH2 CH)
7.25 8 (s, 5H, ArH)
13C NMR See table 2_j_2
Analysis See table 2.3
293-Hydroxy-3-phenylquinuclidine (2♦61)
To a solution of phenylmagnesium bromide in anhydrous THF 
[prepared from bromobenzene (12.56g, 0.08 mol) and magnesium 
turnings (1.92g, 0.08 mol)] was added dropwise a solution of 
3-quinuclidone 2.44. (2.5g, 0.02 mol) in anhydrous THF (50 ml), 
and the mixture heated under reflux for 16 hours. The cooled 
mixture was basified with 2N (200 ml) and extracted with
CHClg (3 x 100 ml). Drying (MgSO^) and removal of solvent gave 
crude 2.61 as a yellow oil (4.8g). Crystallisation from petroleum 
ether (60-80°)-Me2C0 gave 2.61 (2.3 g, 57Z) as a pale crystalline 
solid, m.p. 170 - 172°C (lit 29 m.p. 166.8°C).
] . -
1H NMR 1.4 - 2.1 5 (m, 4H, 2 x CH2)
2.4 - 2.6 8 (m, 1H, C^H)
3.2 - 3.9 8 (m, 7H, 3 x NCH2 , OH)
7.3 - 7.7 8 (m, 5H, Ar-H)
13C NMR See table 2.2
3-Acetoxy-3-phenylquinuclidine (2.62)
A solution of 2.61 (0.8g, 0.004 mol) in acetic anhydride (20 ml) 
was heated to 80°C for 3 hours, then cooled and acidified with 
2N HC1. The mixture was washed with Et20 (3 x 100 ml; discarded) 
then basified with 2N NaOH and extracted with Et20 (3 x 100 ml) . 
Drying (MgSO^) and removal of solvent gave crude 2♦62 as a yellow 
oil (0.95g). The hydrochloride salt crystallised from 
Et20 - EtOAc as a white solid (0.7g, 632) and had m.p. 200-l°C.
1H NMR 1.2 - 2.1 8 (m, 3H, 2 x CH2)!
1.9 8 (m, 3H, CH3)
2.3 - 4.2 8 (m, 7H, 3 x NCH£, CH)
7.2 - 7.6 8 (m, 5H, ArH)
13C NMR See table 2.2
Analysis See table 2.3
3-Propionoxy-3-phenylquinuclidine (2.63)
A solution of 2.61 (1.3g, 0.0064 mol) in propionic anhydride (30 
ml) was heated to 80°C for 5 hours. Work up as for 2.62 gave 
crude 2.63 as a yellow oil (0.95g). The hydrochloride salt 
crystallised from Et20 - EtOAc as a white solid (0.55g, 292). 
m.p. 118°C.
XH NMR 1.1 8 (t, J=8Hz, 3H, CH3 )
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1.2 - 1.8 8 (m, 4H, NCH2 CH2)
2.3 8 (q, J=8Ez, 2H, C0CH2)
2.4 - 3.1 8 (m, 5H, NCH2-CH2 , C4H)
3.5 8 (AB q, J=15Hz, 2H, NCH2CAr)
7.1 - 7.6 8 (m, 5H, ArH)
C NMR See table 2.2
Analysis See table 2.3
2-Benzyl-3-hydroxy-3-phenylquinuclidine (2.64)
To a solution of phenyllithium in anhydrous Et20 (100 ml) prepared 
from bromobenzene (3.8g, 0.0242 mol) and lithium (0.34g, 0.0484 
mol) and left to stir at 20°C for 1 hour, was added (with cooling) 
a solution of 2.55 (2.6g, 0.0121 mol) in anhydrous Et20 (100 ml). 
The mixture was stirred at 20°C for 3 hours then poured into a 
mixture of H20 (100 ml) and Et20 (100 ml). The aqueous layer was 
separated and basified with 2N Na2C03 , then extracted with Et20 (3 
x 100 ml). Drying (MgSO^) and removal of solvent gave crude 2.64
as a yellow oil (3.3 g). Distillation in a Kugel Rohr apparatus
gave 2.64 (3.0g, 852) as a pale yellow oil which solidified on
standing, b.p. 210°C § 0.4 mmHg.
IR (CDC13 ) 3560 cm-1 (0 - H)
1H NMR 1.2 - 3.1 8 (11 aliphatic H)
3.2 8 (br s, 1H, OH exchanges with D20)
3.8 8 (br t, J-7.5 Hz, 1H, Ar-CH)
7.0 - 7.7 8 (m, 10H, ArH)
including 7.2 8 (s, 5H, ArH)
13C NMR See table 2.2 '
( No C,H,N data available )
2-Benzyl-3-acetoxy-3-phenylquinuclidine (2.65)
and including the preparation of
2-Benzyl-3-phenyl-A. 2.3-quinuclidene (2.66)
A similar method to the synthesis of 2.64 was used with a 
variation in the work-up procedure.
After stirring the mixture for 3 hours at 20°C, acetic anhydride 
(2g) was added and the mixture heated to 50°C for 2 hours, then 
cooled and poured into a mixture of acetic acid (100 ml) and Et20
(100 ml). The aqueous layer was separated, basified with 2N
Na2C03 and extracted with Et20 (3 x 100 ml). Drying (MgSO^) and
removal of solvent gave a yellow oil (3.4g). This was
chromatographed on silica gel (50g) using EtOAc - CHCl^ mixtures 
as eluant.
1 1 i
2.66 was obtained as an off-white solid (0.3g, 9Z). The 
hydrochloride salt crystallised from EtOAc - P r ^ H  as a white 
crystalline solid m.p. 198-200°C.
EIMS M/Z 275 (M+)
IR (KC1) (Hydrochloride) 1600 cm"^ weak (C = C)
3.0 8 (m, 9 aliphatic H)
3.55 8 (s, 2H, CH2Ph)
7.15 8 (s, 5H, ArH)
7.20 8 (s, 5H, ArH)
13C NMR See table 2.2
Analysis See table 2.3
A further 1.6g of combined column fractions were converted to the 
oxalate salt. This crystallised from (slowly over several
days) as colourless needles. Liberation of the free base gave
2.65 (0.8g, 21Z) as a colourless oil. The hydrochloride salt 
crystallised from EtOAc - as a white solid m.p. 175-7°C.
NMR 1.2 - 1.8 6 (m, 5 aliphatic H)
2.0 8 (s, 3H, COCH3)
2.5 - 3.5 8 (m, 7 aliphatic H)
7.1 - 7.7 8 (m, 10H, ArH)
13C NMR See table 2.2
Analysis See table 2.3
3-Phenyliminoquinuclidine (2.67)
A mixture of 2.44 (9g, 0.072 mol), zinc chloride (lg) and toluene 
(200 ml) were azeotropically distilled in a Dean-Stark apparatus 
for 16 hours. The cooled mixture was filtered and distilled under 
reduced pressure to give 2.67 (11.05g, 77Z) as a colourless oil, 
b.p. 125° g 0.2 mmHg .
H NMR 1.6 - 2.2 6 (m, 4H, 2 x NCH2CH2 )
2.7 - 3.2 6 (m, 5H, 2 x NCH2 , C4
3.4 8 (s, 1H, NCHC-N)
3.6 8 (s, 1H, NCHON)
6.7 - 6.9 8 (m, 2H, ArH)
7.0 - 7.5 8 (m, 3H, ArH)
13C NMR See table 2.2
3-PhenylamA inoquinuclidine (2.68)
To a stirred mixture of LAH (8g, 0.21 mol) in anhydrous THF (100 
ml) was added, dropwise, a solution of 2.67 (llg, 0.055 mol) in 
anhydrous THF (100 ml). The mixture was refluxed for 1 hour then 
cooled in an ice bath. After cautious dropwise addition of 2N 
NaOH (15 ml) and 1 hour stirring at 10°C, the slurry was filtered
and the cake washed with CH2C12 (200 ml). Drying (MgSO^) and 
removal of solvent gave a yellow solid which crystallised 
from cyclohexane to give 2 .68 (5.96g, 54Z) as a white solid, m.p. 
112°C.
1H NMR 1.2 ■ 2.1 5 (m, 5H, 2 x C H „  CH)
2.3 - 3.1 6 (m, 4H, 2 x CH2N)
3.2 - 3.6 8 (m, 2H, CH2N)
3.8 8 (br s, 1H, NH, exchanges with D20)
6.4 - 6.8 8 (m, 3H, ArH)
7.0 - 7.3 8 (t, J-7.5Hz, 2H, ArH)
13C NMR See table 2.2
3-(N-acetvlanilino)quinuclidine (2.69)
A solution of 2 .68 (2g, 0.01 mol) in acetic anhydride (15 ml) was 
heated to 80°C for 1 hour. Work up as for 2.62 gave crude 2.69 as 
a yellow oil (2.3g). The hydrochloride salt crystallised from 
EtOAc-Me2CO as a pale solid (l.lg, 40Z), m.p. 192-3°C.
~*~H NMR 0.9 - 3.9 8 (m, 14 aliphatic H)
including 1.8 8 (s, 3H, COCH^)
4.7 8 (br t, J«=8 .5Hz, 1H, C3H)
7.15 - 7.6 8 (m, 5H, ArH)
13C NMR See table 2.2
Analysis See table 2.3
12.1
3-(N-propionylanilino)quinuclidine (2.70)
A solution of 2 .68 (2g, 0.01 mol) in propionic anhydride (15 ml) 
was heated to 80°C for 3 hours. Work up as for 2.62 gave crude 
2.70 as a yellow oil (2.7g). The hydrochloride salt crystallised 
from EtOAc-EtOH as a white solid (0.6g, 20Z), m.p. 183-4°C«
1H NMR 1.0 8 (t, 3H, CH3)
1.5 - 2.3 8 (m, 6 aliphatic H)
2.5 - 3.0 8 (m, 6 aliphatic H)
3.4 8 (br t, J=7.5 Hz, 1H, C4H)
4.7 8 (br t, J=7.5 Hz, 1H, C3H)
7.1 - 7.6 8 (m, 5H, ArH)
13C NMR See table 2.2
Analysis See table 2.3
3-(N-propylanilino)quinuclidine (2.71)
To a stirred mixture of LAH (0.75g, 0.02 mol) in anhydrous THF 
(25 ml), was added dropwise a solution of 2.70 (1.3g, 0.005 mol) 
in anhydrous THF (25 ml). The mixture was heated under reflux for 
16 hours then cooled in an ice bath. Work up as for 2 .68 gave a 
pale solid (l.Og). Recrystallisation from Me2C0 gave 2.71.
(0.70g, 57Z) as white crystals, m.p. 217-219°C. The hydrochloride 
salt was found to be hygroscopic and could not be obtained pure. 
The oxalate salt crystallised from EtOH as a white solid, m.p. 
162-3 °C.
1 ? 9
1% moles of oxalic acid per mole of base from analytical results 
(table 2.3).
EIMS M/Z 244 (M+)
2.1 8 (m, 9 aliphatic H)
0.8 8 (t, J=7.5Hz, 3H, CH3)
3.6 6 (m, 10 aliphatic H)
7.5 8 (m. 5H, ArH)
13C NMR See table 2.2
Analysis See table 2.3
2-Benzyl-3-phenyliminoquinuclidine (2.72)
A mixture of 2.55 (5.2g, 0.0242 mol), freshly distilled aniline 
(llg, 0.121 mol), zinc chloride (0.75g) and toluene (150 ml) were 
azeotropically distilled in a Dean-Stark apparatus for 6 days.
The cooled mixture was filtered and distilled under reduced 
pressure to give crude 2.27 as a red oil (6.1g). This was 
crystallised, first from petroleum ether (60 - 80°) then petroleum 
ether (30 - 40°), to give 2.72 (2.2g, 312) as pale yellow 
crystals, m.p. 72-3°C.
1H NMR 1.6 - 2.1 8 (m, 4H, 2 x CH£)
2.6 - 4.0 8 (m, 8 aliphatic H)
6.8 - 7.6 8 (m, 10H, ArH)
13C NMR See table 2.2
Analysis See table 2.3
2-Benzyl-3-phenylanilinoauinuclidine (2 .73)
To a stirred mixture of LAH (1.89g, 0.05 mol) in anhydrous THF (30 
ml) was added, dropwise, a solution of 2.72 (3.6g, 0.0124 mol) in 
anhydrous THF (30 ml). The mixture was heated under reflux for 1
hour, then worked up as for 2 .68 to give 2.73. (2.5g, 69Z) as pink
crystals, m.p. 122-3°C.
~^ H NMR 1.4 - 2.2 8 (m, 6 aliphatic H)
2.5 - 3.4 8 (m, 8 aliphatic H)
including 3.3 8 (br s, NH, exchanges with D20)
7.4 8 (s, 5H, ArH)
13C NMR See table 2.2
Analysis See table 2.3
2-Benzvl-3-(N-propionylanilino)Quinuclidine (2.74)
A solution of 2♦73 (2.3g, 0.008 mol) in propionic anhydride 
(25 ml) was heated to 80°C for 3 hours. Work up as for 2.62 
gave crude 2.74 as a yellow oil (2.5g). Crystallisation from 
petroleum ether (40 - 60°) gave 2.74. (1.8g, 66Z) as yellow 
crystals m.p. 82-4°C. The hydrochloride salt crystallised from 
benzene-Me2C0 as white granules, m.p. 208-9°C.
NMR 0.9 - 1.4 8 (m, 5 aliphatic H)
including 1.0 8 (t, J=7.5Hz, 3H, CH3)
1.5 - 2.5 8 (m, 5 aliphatic H)
2.6 - 3.5 8 (m, 7 aliphatic H)
4.8 8 (m, 1H, CHNAr)
13C NMR See table 2.2
Analysis See table 2.3
TABLE 2 . 2 ___ 13C MVIR DATA ON SOME 2 , 2 , 3  & 2 , 3 , 3  SUBSTITUTED QUINUCLIDINES
Compound Benzyl ArCO COR Aromatics
2 . 4 4 6 2 . 9 2 0 4 . 2 3 9 . 7 2 5 . 8 4 7 . 0
2 . 4 5 130 2 0 5 . 3 4 0 . 4 . 2 8 . 2 4 7 . 6 1 2 4.6-1 4 4 . 0
2 . 5 5 7 2 . 4 2 0 7 . 5 4 9 . 8 2 6 .1 ,2 7 . 6 3 4 .5 ,4 1 . 0 4 1 . 9 1 2 7 .2-1 4 0 . 0
2 . 6 1 6 0 . 8 7 2 . 5 3 2 . 9 2 0 .2 ,2 1 . 4 3 3 .5 ,4 1 . 2 1 2 7.0-1 4 4 . 6
2 . 6 2 5 9 . 7 8 2 . 3 3 1 . 6 22.8 4 6 .3 ,4 7 . 3 1 6 9 . 7 21.8 1 2 5.8-1 4 2 . 6
2 . 6 3 5 9 . 9 8 2 . 1 3 1 . 6 2 2 . 9 4 6 .4 ,4 7 . 4 1 7 3 . 0 2 1 .9 ,2 8 . 4 1 2 5.8-1 4 2 . 6
2 . 6 4 6 4 . 3 7 5 . 2 3 5 . 8 2 1 .9 ,2 3 . 3 3 3 .4 ,4 1 . 1 4 8 . 9 1 2 5 .8-1 4 6 . 4
2 . 6 5 6 8 . 9 8 4 . 0 3 3 . 2 2 3 .0 ,2 3 . 6 2 8 .0 ,4 1 . 1 4 8 . 7 1 6 9 . 6 2 1 . 7 1 2 5.8-1 4 2 . 0
2.66 126 128 3 4 . 3 2 9 . 5 3 7 . 5 4 9 . 3 1 2 6 .0-1 4 6 . 4
2 . 6 7 5 5 .5 ,5 9 . 5 1 7 9 .8 ,1 8 0 . 8 2 8 .3 ,3 5 . 5 2 6 .1 ,2 6 . 5 4 7 . 2 1 1 9 .1-1 5 0 . 6
2.68 5 7 . 2 5 0 . 3 2 5 . 2 2 0 .1 ,2 6 . 1 4 6 .9 ,4 7 . 5 1 1 3 .2-1 4 7 . 5
2 . 6 9 5 3 . 6 5 3 . 4 2 5 . 9 2 0 .8 ,2 8 . 9 4 6 .5 ,4 7 . 7 1 7 1 . 3 2 3 . 6 1 2 8 .5-1 4 1 . 1
2 . 7 0 5 3 . 8 5 3 . 6 2 5 . 9 2 0 .8 ,2 8 . 9 4 6 .6 ,4 7 . 6 1 7 4 . 4 9 .5 ,2 8 . 5 1 2 8 .4-1 4 0 . 6
2 . 7 1 5 5 . 1 5 4 . 3 2 4 . 3 2 0 .5 ,2 4 . 3 4 7 .0 ,4 7 . 7 1 1 .6 ,1 9 .7 ,2 6 . 8 1 2 1.5-1 5 0 . 6
2 . 7 2 6 7 . 9 1 8 2 . 2 2 9 . 0 2 6 .0 ,2 6 . 8 3 6 .5 ,4 1 . 1 4 9 . 3 1 1 9 .5-1 5 1 . 1
2 . 7 3 6 7 . 1 5 8 . 0 2 6 . 2 1 9 .8 ,2 6 . 0 3 9 .8 ,4 1 . 4 4 9 . 9 1 1 3.4-1 4 7 . 6
2 . 7 4 6 1 . 2 5 8 . 9 2 9 . 7 2 1 .3 ,2 8 . 8 3 9 .2 ,4 1 . 3 4 9 . 6 1 7 4 . 3 9 .6 ,2 8 . 7 1 2 6.0-1 4 0 . 3
1 2 6
Analytical Data Table 2.3
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The 6 ,7-benzomorphan class of compounds (described in Chemical
Abstracts as the 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines)
are an extensively investigated and important class of synthetic
1 2narcotic analgesics. * The parent ring system of the original 
(benzomorphan) and Chemical Abstracts numbering systems are shown 
in 3 .1 and 3 ♦2 respectively.
In this chapter, the original nomenclature has been used 
throughout.
Metazocine 3.3 is usually regarded as the parent 6 ,7-benzomorphan. 
The 5,9 methyl groups can be oriented either cis as 3.3a. or trans 
as 3.3b. These isomers are designated the a and J3 isomers 
respectively.
2 ’ 1 ’ 8 7




A marked difference in biological activity exists between these 2 
isomers, with the £  isomer approximately 10 times more active in 
rodent tests.^
Due to the chirality of positions 1 and 5, an antipodal pair exists 
for each (a or £) benzomorphan.
When the antipodal pairs are resolved, the vast majority of the 
analgesic activity is found to reside in the laevo benzomorphan, 
which is configurationally related to (-) morphine. The dextro 
enantiomers of 3.3a/b are analgesically inactive and generally more 
toxic than their laevo counterparts.
One of the best known of the 6 ,7-benzomorphans is pentazocine 3.4.
3




The 6 ,7-benzomorphans were originally synthesised in the early 
1950s, during attempts to rationalise the structure of morphine 3.5 
and in doing so separate its analgesic properties from undesired 
side effects (respiratory depression, physical dependence
liability (PDC), etc.) This approach was furthered by the
discovery that the morphinan levorphanol 3.6. obtained by removal
of functional groups from morphine, was 3 to 4 times more potent,
a
whilst showing a similar level of side effects.
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Extrapolation of these results by further rationalisation of the 
morphinoid structure, for example as in the 6 ,7-benzomorphans, 
might therefore seem a promising strategy.
Since these early experiments, a large number of 6 ,7-benzomorphans 
have been synthesised and their pharmacology investigated. In 
general, the structure-activity profiles of the 6,7-benzomorphans 
parallel those seen in the morphine and morphinan series. For 
instance, introduction of a phenolic OH at position 2* increases 
activity, whilst masking the oxygen function as, for example, the 
methyl ether reduces it (c.f. morphine and codeine). Acetylation 
at 2 ’ generally increases activity compared to the parent phenolic 
derivative (c.f. morphine and heroin).
However, there are exceptions and activity may often be highly 
dependent on the overall substitution pattern. For instance, in
3.7 introduction of OH at 2* did not increase activity in rodent 
tests although 0,-methylation did reduce it. This is in contrast to
3 .8 which showed the expected pattern of activity, i.e. OAc at 2*































One of the original synthetic methods used for the preparation of 
the 6,7-benzomorphans is illustrated in scheme 3.1.^
Alkylation of methylbenzyl cyanide 3.10 with
l-chloro-2-dimethylaminoethane 3.9 in the presence of base gave 
3.11. which was selectively reduced to the aldehyde 3.12. 
Condensation of 3.12 with methyl cyanoacetate 3.13 gave 3.14 which 
was hydrogenated over Adams catalyst . Subsequent hydrolysis 
and decarboxylation gave amino acid 3.15. Intramolecular 
ring closure, bromination and further cyclisation led to the 
methobromide of 3.18. Elimination of methyl bromide, followed by 
Wolf-Kishner reduction gave 5-methyl-6,7-benzomorphan 3.19 in 52 
overall yield. A phenolic OH could subsequently be introduced at 







3^11 R=CN R1 = (CH2 )2NMe2 












3^20 R=N02 R1=H2 
3_J_9 R=H R1=H2
3^18 R=H R1=0 (methobromide)
NMe
Me





SCHEME 3 .1  6
A later method which has found wide use in the synthesis of
6 .7-benzomorphans is the Grewe^ synthesis. This was originally 
used for the synthesis of morphinan derivatives and has since been 
successfully adapted for use with 6,7-benzomorphans. The Grewe
O
method is illustrated for the synthesis of 3.27 in scheme 3.2 . 
Reaction of 1,3,4-trimethylpyridinium iodide 3.23 with 
jD-methoxybenzylmagnesium chloride gave 3.24 ♦ The enamine double 
bond was reduced with sodium borohydride to give 3.25 which 
cyclised under acid conditions to give the
2, 5, 9-trimethyl-2’ -methoxy-6 , 7-benzomorphan 3.26. 0_-Demethylation 
with HBr gave the 2 ’-hydroxy derivative 3.27. The overall yield 
was approximately 25Z.
One major advantage of the Grewe method is the ability to alter the 
alkyl substitution pattern of the final product by choice of 
suitably substituted pyridine starting material.
Structure-Activity Relationships
As in the morphine and morphinan series, variation of substituents 
on the aromatic ring, on nitrogen and elsewhere in the
6 .7-benzomorphan system may have a profound effect on the type and 
magnitude of biological activity. The most frequently found 
structure variations used to bring about these changes are at the 
2 ’, 2, 5 and 9 positions.
2* Substituents
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SCHEME 3 .2  8
in the morphinan series. A change from H to OH usually effects an 
increase in activity which is further increased by acetylation. 
Conversely, analgesic activity is decreased when the phenolic OH is 
masked (usually by methylation).
Structure 3.28 and the analgesic activity of some derivatives are 
shown as examples in table 3.2









OCOA r N02 0.41
mo rph i ne 1.2
suIpha te
TABLE 3.2 1 (ED50 mg/kg MHP)
ANALGESIC ACTIVITIES OF SOME 




The effect of substitution at nitrogen again parallels that seen in 
the morphine/morphinan series. Alkyl groups other than methyl tend 
to have reduced agonist activity (i.e. ethyl > propyl > butyl) 
whereas n-pentyl is approximately equipotent. Several aralkyl 
groups confer increased agonist activity on the system; the most 
commonly used is the phenethyl group. Others which have been found 
to be effective are £-aminophenethyl, thienylethyl and
2-tetrahydrofurfuryl. The N-thienylethyl derivative, 3.29. is 




Substitution of N-methyl lyj allyl, cyclopropylmethyl (CPM) and 
certain others, for example furylmethyl, generally confer 
antagonist properties on the benzomorphan system. For example, the 
N-furylmethyl benzomorphan 3.30^  is approximately equipotent as an 
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Other Substituents
9-Substituents
The introduction of a hydroxyl group at position 14 in morphinoid 
compounds generally increases agonist activity. Thus, 
14-hydroxydihydromorphinone 3.32 is found to be between 2 and 4 
times more potent than dihydromorphinone 3.32a.^
HO
3^32 R=OH R1=Me 
3_J32a R=H R1=Me 
3^33 R=OH Rt = a I I y I 
3L33a R=OH R1=CPM
Several therapeutically well known narcotic antagonists are 
14-hydroxy substituted e.g. naloxone 3.33 and naltrexone 3.33a.
Introduction of a hydroxyl group at the corresponding position 9 in 
the 6,7-benzomorphans usually results in a reduction in analgesic 
















When R was ethyl, activity was reduced by the introduction of a 
9-hydroxyl J3 (trans) as in 3.34. and abolished altogether when the 
9-hydroxyl was oriented towards the nitrogen (a form, 3.35) . This 
pattern was reversed when R was methyl, as in 3.39. The 
9a-hydroxy derivative 3♦38 was approximately one-eighth as active 
as 3 .39 ^ whereas the 9£~hydroxy derivative 3.37 was inactive. ^
BENZOMORPHAN DISCUSSION
Derivatives of the 6 ,7-benzomorphans 3.40 constitute a class of
1 2compounds with opiate-like analgesic activity. *
3 ^ 4 0




3^43 R=aI Iy I
Over the past few decades, a large number of 6,7-benzomorphans have 
been synthesised, not only in an effort to produce a potent 
analgesic with the minimum of undesired properties, but also as a 





this problem in the benzomorphan series has been the optical
12resolution of enantiomeric isomers. It has been shown that the 
laevo forms of the benzomorphans are configurationally related to 
morphine and are predominantly responsible for the analgesic 
properties of the racemate. Additionally, several (-) 
benzomorphans have been shown to lack a physical dependence 
capacity (PDC) in rhesus monkeys.12-14
In the late 1970s the optical resolution of (±)





was achieved and amongst others, the (-)-9j3 isomer was shown to 
warrant further investigation as a potent analgesic with little or 
no PDC.15 However, due to the relatively complex and low yielding 
method (necessarily involving fractional crystallation of 
diastereomeric salts) we were led to investigate an alternate 
stereospecific route to these compounds.
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Historical Background
In the 1920s, during the course of a structure determination of 
morphine using chemical degradation to known products, Schopf^® 
subjected dihydrocodeinone oxime, 3.45. to Beckmann rearrangement 
and isolated
(-)- 9a-(2-c yanoe thy1)-5a-fo rmy 1-1 * -hyd roxy-2’ -me th oxy-6,7-benzomo rp— 
han 3.46 as the major product (scheme 3.3).
Me Me
- • ■ m i
SOCI
'CHO




Appropriate substituents of this type in the 5 and 9 positions of
3.46 offered the possibility of preparing a series of optically 
pure (-)-5,9-dialkylbenzomorphans similar in nature to 3 .44. in 
reasonable yield without the need for optical resolution.
The conversion of 3.46 to a 5,9-dialkyl derivative similar to 3.44 
requires the reduction of the 5 and 9 substituents and 
deoxygenation at position 1 *, together with 0,-demethylation of the 
2'-methoxy substituent. During the course of these transformations 
in this laboratory, cyclisation occurred to give a series of 5a,
1 *-methyleneoxybenzomorphans exemplified by the 2 ‘-hydroxy 
derivative, 3.54. The new methyleneoxy ring was subsequently 
opened to give the 1 *-hydroxy and 1 *-methoxy-6 ,7-benzomorphans,




3 . 5 4
3J50 R=H 
3 .6 1  R=Me
Other workers have previously synthesised 5a,1 ’-methyleneoxy- 
6,7-benzomorphan derivatives. In 1967, workers investigating the 
ozonolysis of thebaine isolated low yields of 3 .47. but no 
biological data were presented.^
Me CH2CH2Ph





18In 1963, a group converted codeine via
N-phenethyl-7,8-dihydroxydihydro desoxycodeine into the
5a,1 *methyleneoxy benzomorphan 3.48 which had twice the potency of
morphine in the mouse hot plate test. Additionally, an oxide
19bridged 5-(m-hydroxyphenyl)morphan 3.49a was recently reported , 




5-(m-hydroxyphenyl)morphan 3.49. The constrained stereochemistry 
of the phenyl ring in 3.49a was presumed to be unsuitable for 
binding to the opioid receptors.
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The investigation of these 5a,1 ’-methyleneoxy-6,7-benzomorphans may
shed further light on the role of both the C ring and aromatic
20oxygenation m  morphmoid systems.
Chemistry
Treatment of dihydrocodeinone oxime 3.45 with thionyl chloride 
afforded 2 products as determined by TLC. The major product 3.46 
was isolated by recrystallisation from methanol and is the 
secondary or ’abnormal’ Beckmann product. The remaining compound 
proved extremely labile, decomposed on handling, and could not be 
isolated or characterised. In the absence of other evidence this 








3 ♦ 46 was eventually obtained in 30Z yield after several 
crystallisations from methanol. Reduction of the aldehyde group in
3.46 with sodium borohydride in ethanol gave the corresponding 
alcohol 3.50. Alcoholysis of the nitrile group in 3.50 with 
anhydrous ethanol and concentrated f^SO^ not only produced the 
corresponding ester, but also, through protonation of the alcohol 
group and attack by the phenolic hydroxyl group, effected 
cyclisation of the furan ring to the 5a-furano derivative 3.51.


























The NHR spectrum of 3.51 showed the new furan ring methylene 
proton signal as an AB quartet centred at 8 ■ 4.41 ppm (J=8Hz), 
(figure 3.2), c.f. -CH^OH in 3.50 with 8 * 4.0 ppm (figure 3.1).
Ester 3.51 was readily reduced in high yield to the alcohol 3.52 
using lithium aluminium hydride (LAH) in THF. 3.52 was further
21reduced to 3.53 by modification of a previously published method.
Methyl triphenoxyphosphonium iodide in anhydrous THF converted 3.52
to the corresponding alkyl iodide which was not isolated but was
reduced jm situ to 3.53 with sodium cyanoborohydride (scheme 3.5).
0,-Demethylation of 3.53 was achieved with a solution of boron
22tribomide in chloroform J 3.54 was obtained in high yield 
(scheme 3.6).
Acetylation of 3♦54 with acetyl chloride in the presence of 
triethylamine gave 3.55 (scheme 3.7).
Preparation of the N-allyl and N-phenethyl derivatives, 3.57 and
233.58 respectively, was achieved via N-demethylation of 3.54 
followed by reaction of the resulting secondary amine 3.56. with 
the appropriate alkyl halide. Thus, reaction of 3.54 with 
2 ,2 ,2-trichloroethyljchlorofonnate and potassium carbonate in 
toluene gave the trichloroethylcarbamate ester,which hydrolysed 
under the influence of zinc and acetic acid to give 3.56 (scheme 
3.8) .
FIGURE 3 .1
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SCHEME 3 .8
Reaction of 3.56 with an excess of allyl bromide gave mixtures of 
N-allyl and N.O-diallvl material (scheme 3.9). Pure 3.57 was 
separated from the crude mixture by extraction of its sodium salt 
into aqueous sodium hydroxide solution. This procedure accounts 
for the low yield for the conversion.
Reaction of 3.56 with phenethyl bromide also required an excess of 
alkyl halide for satisfactory yields of the N-phenethyl compound
3.58 (scheme 3.9). This also led to substanial 0,-alkylation. Due 
to the poor solubility of the sodium salt of 3.58 in aqueous media, 
the separation technique for 3.57 failed.
However, yields of 3.58 were substantially increased by 
O-dealkylation of the crude product with boron tribomide.
159
H














Reduction of the 5.1'-Furan Ring in 3.54
First, hydrogenolysis of the 2*-hydroxy group in 3.54 was achieved
through conversion to its 2 ’-(1-phenyltetrazole) derivative, and
subsequent cleavage by catalytic hydrogenation over a palladium 
24catalyst gave 3.59 (scheme 3.10). Ring opening of 3.59 was 
achieved using an excess of LAH in TKF. Conventional work-up 
procedures had previously led to poor recovery of 3.60. but 
considerable improvement was obtained by addition of the crude 
reaction slurry to a stirred mixture of aqueous sodium carbonate 
and chloroform, followed by further chloroform extraction of the 
aqueous layer (see experimental section).
Structural assignment of 3.60 was supported by the loss of the 
furan (5*) ring protons and the associated upfield resonance at 8 ■ 
1.8 ppm for the 5-methyl protons (figure 3.3).
The l>methoxy derivative 3.61 was obtained in low yield by 
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In addition to the above series of benzomorphans, a novel
homo-oxa-derivative of N-methyl morphinan, hemiacetal 3.62^was 
25obtained via reduction of the nitnle group in 3.50 with the 
selective reducing agent, diisobutylaluminium hydride (DIBAL) 
(scheme 3.12).
1 13The structure of 3.62 was supported by its K and C NMR spectra 
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FIGURE 3 .4
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Discussion of Biological Results
Since (-)-2,5-dimethyl-2’-hydroxy-9a-propyl-6,7-benzomorphan (3.44) 
has been reported to show similar levels of analgesic potency to 
morphine and has also been demonstrated to lack a PDC in rhesus 
monkeys^, similar levels of activity were expected in the 
5a,1 *-methyleneoxy-9a-propyl-6,7-benzomorphans (3.54 - 3.58).
The 2 ’-hydroxy derivative 3.54 showed a level of potency 
approximately two thirds that of morphine in the mouse hot plate 
test (MHP), with an ED5Q of 1.8 mg/kg (table 3.3). 3.54 also
showed the highest potency of the group in both the mouse tail 
flick (MTF) and paraphenylquinone writhing test (PPO), with ED^q S 
of 0.4 and 0.1 mg/kg respectively.
Masking of the phenolic OH by methyl, as in 3.53, or its removal as 
in 3.59. caused loss of activity in the MHP test. Although there 
are exceptions known, for example those previously mentioned (e.g.
3.28), this result is broadly in line with those of other 
5,9-dialkyl-6,7-benzomorphans, where the non-phenolic derivatives 
are generally less potent; however masking of the 2* phenolic OH by 
an acetoxy group as in 3.55. or its removal^as in 3_15£>also 
abolished analgesic activity.
Acetylation of the 2 ’ position in morphinoid systems often 
enhances, rather than reduces, agonist activity (c.f. heroin and 
morphine).
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TABLE 3 . 3  ANALGESIC ACTIV IT IES OF 3 . 5 1 - 3 . 6 2
Compounda MHPb MTFC PPOd MTFe
3.51 IAf (50) IAf (30) g IAf (30)
3.52 IAf (20) IAf (10) IAf (30)
3.53 IAf (20) 8.1(2.3-28.2) 0.8(0.3-2.8) IAf (30)
3.54 1.8(1.3-2.6) 0.4(0.2-0.8) 0.1(0.06-0.2) IAf (30)
3.55 g 0.7(0.5-1.0) 0.2(0.1-0.3) IAf (30)
3.57 IAf (20) IAf (30) g 0.4(0.1-1.0)
3.58 1.7(1.4-2.1) 1.4(0.9-2.4) 0.2(0.1-0.4) IAf (30)











See over for key
KEY FOR TABLE 3.3
a : Compounds tested as hydrochloride salts in water
b : Mouse hot plate test (ED^q mg/kg)
c : Mouse tail flick test (ED^q mg/kg)
d : Phenylquinone writhing test (ED^q mg/kg)
e : Mouse tail flick antagonist assay vs morphine
f : IA*=Inactive at the dose level indicated
g : Low level of activity exhibited
The 2*-hydroxy group therefore seems particularly necessary for MHP
activity in these 5a,1 ’-methyleneoxy-6,7-benzomorphans.
The N-phenethyl derivative 3♦58 showed significant activity in the 
MHP test, with an ED^q of 1.7mg/kg, a similar potency level to that 
of 3.54. although lower levels of activity were exhibited in the 
MTF and PPO tests. These results for 3.58 are against the general 
trend seen in other 6,7-benzomorphans were substitution of methyl 
by phenethyl on nitrogen generally increases activity.
The N-allyl derivative 3.57 was inactive as an analgesic agonist, 
but showed itself to be an antagonist of morphine (AD^q 0.4mg/kg: 
one tenth as active an antagonist as nalorphine).
Other Derivatives
The 1 ’-hydroxy and 1 ’-methoxy-5a-methyl-9a-propyl-6,7-benzomorphans
3.60 and 3.61 respectively, lacked analgesic activity in the MHP 
test as did hemiacetal 3.62. 3.61 might be regarded as
stereochemically similar to the 5a,1 *-methyleneoxy derivative 3.59 
which was also inactive in the MHP test. The 1*-hydroxy group may 
be less stereochemically suited to bind to the receptor than the 
2 '-hydroxy group as in 3.54. Hemiacetal 3.62 also possesses 
1 ’-hydroxy and 2 ’-methoxy substituents which, as in the previous 
examples, seem to be unsuitable for satisfactory receptor binding.
Experimental Section
Infra-red spectra were recorded on a Unicam SP1025 spectrometer.
Melting points (uncorrected) were taken on a Gallenkamp melting 
point apparatus.
13C NMR spectra were recorded on a JEOL FX90Q spectrometer 
operating at 22.5 MHz. The multiplicity of the resonances was 
obtained by either off-resonance (partial 1H coupling) spectra, or 
by INEPT (Insensitive Nuclei Enhanced by Polarisation Transfer) 
spectra in which the phase of the signal indicated the number of 
protons attached to each carbon atom.
NMR spectra were recorded using JEOL JNM-PMX 60 SI, JEOL PS100 
and JEOL GX400 spectrometers. NMR samples (as bases unless stated 
otherwise) were prepared in 5mm o.d. tubes as approximately 10Z 
solutions in CDCl^ (unless stated otherwise) with TMS as reference.
Mass spectra were recorded on a VG 7070E mass spectrometer 
operating at 70 eV (El).
Optical Rotations were measured on an Optical Activity Ltd AA-10 
polarimeter.
Elemental analyses were performed by Butterworths Laboratories 
Ltd., Middlesex.
17?
Formulae and abbreviations as used in. the experimental section
CDC13 Deuterochloroform
c h c i 3 Chloroform
c h 2c i 2 Dichloromethane





h 2s o 4 Sulphuric Acid
k 2c o 3 Potassium Carbonate
MeOH Methanol
Me2CO Acetone
MgS04 Magnesium Sulphate (anhydrous)
NaOH Sodium Hydroxide






Solvent was removed - denotes evaporation under reduced pressure 
using a rotary evaporator.
O g
Dihydrocodeinone oxime (3.45)
A stirred mixture of dihydrocodeinone (117.6g, 0.39 mol), 
hydroxylamine hydrochloride (70g, 1.0 mol), sodium acetate (41g,
0.5 mol) in water (2 L) was heated under reflux for 2 hours, then 
cooled and made alkaline by addition of 10Z aqueous ammonia 
solution. The precipitated oxime was filtered, washed with water 
until washings were neutral, finally washed with EtOAc (400 ml) and 
dried under vacuum at 110°C for 4 hours to give 3.45 (121.8g, 99Z) 
as a white solid, m.p. 262 - 264°C, (lit^ m.p. 264 - 265°C).
EIMS m/z 314 (M+)
( -)-9cx-(2-Cyanoethyl)-5a -formyl-l*-hydroxy-2*-methoxy-2-methyl-6.7-
benzomorphan (3.46)1®
Dihydrocodeinone oxime 3.45 (60g, 0.19 mol) was added in small 
portions to freshly distilled thionyl chloride (210 ml), stirred 
and maintained between -5° and -10°C. The resulting mixture was 
stirred at -5°C for 2 hours, then thionyl chloride removed under 
reduced pressure at below 30°C. Iced water (150 ml) was added 
slowly over 10 minutes, stirred vigorously for 30 minutes to induce 
precipitation and then left overnight at 2°C. The separated solid 
was filtered, washed with cold water (20 ml), then suspended in 
water (100 ml) and heated strongly until no more sulphur dioxide 
and hydrogen chloride was evolved. The filtrate was also heated to 
remove the bulk of sulphur dioxide and hydrogen chloride. The two 
solutions were separately basified with 10Z aqueous ammonia 
solution and extracted with C I ^ C ^  (3 x 200 ml), dried (MgSO^) and 
solvent removed to give crude 3.46. 18.6g and 22.lg respectively. 
Repeated crystallisation from MeOH yielded 3.46 (18.2g, 30Z) as 
colourless crystals, m.p. 195°C (lit'*'® m.p. 190-1°C).
[a]£° -46° (c. 1, 95Z EtOH) .
IR (KBr) 1740 cm"1 (C = 0) 
2270 cm"1 (C s N)
1H NMR 1.5 - 3.3 8 (m, 15 aliphatic H)
including 2.4 8 (s, 3H, NCH3)
3.85 8 (s, 3H, OCH3)
5.7 8 (brs, 1H, OH, exchanges with D2O)
6.7 8 (brs, 2H, 2 x ArH)
9.65 8 (s, 1H, CHO)
13C NMR See table 3.4
Analysis See table 3.5
(-) -9a- (2-Cyanoethyl) -1 * -hydroxy-5a-hydroxyinethyl- 
2*-methoxy-2-methyl-6.7-benzomorphan (3♦50)
To a solution of sodium borohydride (8g) in absolute ethanol (800 
ml) was added finely powdered 3.46 (29.5g, 0.094 mol) in small 
portions. After stirring at room temperature for 1 hour, the 
mixture was filtered, then made acidic with 2N HC1 and the solvent 
removed to give a solid residue. This was dissolved in water (1 L) 
washed with Et20 (3 x 200 ml; discarded), saturated with Na2C03 and
extracted with CHC13 (5 x 300 ml). The combined CHC13 extracts
were dried (MgSO^) and solvent removed to give 3.50 (26.2g, 882) as 
a colourless solid, m.p. 80°C. TLC (MeOH:aq.ammonia 50:1) showed 
the product to be a single component. This product, and its 
hydrochloride and oxalate salts, could not be crystallised.
EIMS tn/z calc’d 316.1787 
found 316.1786
IR (KBr) 2270 cm"^ (C = N)
NMR 1.2 - 3.0 6 (m, 15 aliphatic
including 2.35 5 (s, 3H, NCH3 )
3.8 5 (s, 3H, 0CH3 )
4.0 8 (ABq, J=8Hz, 2H,
5.4 5 (brs, 2H, 2 x OH
6.6 5 (s, 2H, 2 x ArH)
13C NMR See table 3.4.
(-)-9a-(2-Ethoxycarbonyl)ethyl-5a.1 *-methyleneoxy-2 *-methoxy- 
2-methvl-6.7-benzomorphan (3.51)
To a solution of 3.50 (13.5g, 0.043 mol) in ’super dry* ethanol 
(500 ml) was cautiously added cone H2S0^ (200 ml). The solution 
was refluxed for 4 hours then cooled, basified with Na2C03 solution 
and extracted with CHCl^ (5 x 300 ml). The combined organic layers 
were dried (MgSO^) and solvent removed to give crude 3♦51 (12.9g, 
87Z) as a viscous yellow oil. The oxalate salt crystallised from 
Me2C0-Et0H as yellow needles, m.p. 167-170°C. The hydrochloride 
crystallised from EtOAC - EtOH as colourless needles, m.p. 102-3°C.
The liberated free base gave [<*]p " ^1° (■£. ^5Z EtOH)
EIMS m/z 345 (M+)
IR (CHC13) 1735 cm-1 (C - 0)
0.8 - 2.6 5 (m, 16 aliphatic H)
including 1.2 5 (t, J=8Hz, 3H, CH2CH3 )
and 2.4 5 (s, 3H, NCH3)
3.1 6 (m, 2H, NCH2 )
3.8 5 (s, 3H, OCH3)
4.05 8 (q, J=8Hz, 2H, CH.2CH3)
4.4 5 (ABq, J=8Hz, 0CH2C)
6.6 5 (ABq, J=8Hz, 2Ht 2 x ArH)
13C NMR See table 3.4
Analysis See table 3.5
(-)-9a-Hydroxypropyl-5a .1 *-methyleneoxy-2*-methoxy-2-methyl-6.7- 
benzomorphan (3.52)
To a suspension of LAH (7g) in anhydrous THF (200 ml) was slowly 
added a solution of 3.51 (13g, 0.038 mol) in anhydrous THF (500 
ml). After stirring for 1 hour at 20°C, a saturated solution of 
Na2C03 (12 ml) was added slowly dropwise and the mixture diluted 
with CHClj (1 L), dried (MgSO^) and filtered. Removal of solvent 
gave 3.52 (11.2g, 982) as a viscous yellow oil. The hydrochloride 
crystallised from Et20-EtOH as white needles, m.p. 190-2°C.
90
The liberated free base gave [a]^ -43° (£ 1, 952 EtOH).
1H NMR 0.7 - 2.6 8 (m, 15 aliphatic H)
2.4 8 (s, 3H, NCH3)
3.1 8 (m, 2H, N C H 2 )
3.6 8 (br t, J«7Hz, 2H, CH20H)
3.9 8 (s, 3H, 0CH3)
4.05 8 (br s, 1H, OH, exchanges with D20)
4.5 8 (ABq, J=8Hz, 2H, 0CH2C)
6.8 8 (ABq, J=8Hz, 2H, 2 x ArH)
13C NMR See table 3.4
Analysis See table 3.5
1 ° 0
(-)-5a.1 *-Methylenoxy-2 *-methoxy-9a -propyl-6.7-benzomorphan
(3.53)
In a dry box under a nitrogen atmosphere, methyltriphenoxy 
phosphonium iodide (20g, 0.044 mol) was added to a solution of 3.52 
(4.8g, 0.016 mol) in anhydrous THF (150 ml), followed by sodium
cyanoborohydride (5g). The mixture was removed from the dry box,
then heated to 50-60°C for 3 hours, cooled, basified with Na2C03 
solution and extracted with CHCl^ (3 x 200 ml). The organic layers 
were combined and solvent removed to give a crude yellow oil. This 
was dissolved in 6M HC1 (300 ml), washed with Et2<) (3 x 300 ml; 
discarded) basisfied with Na2C03 and extracted with Et20 (5 x 200 
ml). The combined ethereal layers were dried (MgSO^) and solvent 
removed to give 3.53 (3.3g, 72Z) as a viscous yellow oil.
Purification was effected by vacuum distillation at 130°C/0.OlmmHg 
(decomposition starts @ ~ 140°C);3♦53 was obtained as a colourless 
viscous oil (yield 43Z). The hydrochloride crystallised from 
EtOAc-EtOH as colourless needles, m.p. 222-4°C.
The liberated free base gave [a 3 ^  -51° (c. 0.96, 95Z EtOH)
EIMS m/z 287 (M+)
0.85 5 (br t, J=8Hz, 3H, CH2CH2CH.3 )
1.25 - 2.5 8 (m, 10 aliphatic H)
including 2.4 5 (s, 3H, NCH3)
3.1 8 (m, 2H, NCH2)
3.82 8 (s, 3H, 0CH3)
4.4 8 (ABq, J=8Hz, 2H, OO^C)
6.62 8 (ABq, J=8Hz, 2H, 2 x ArH)
13C NMR See table 3.4
Analysis See table 3.5
(-)-8-Hydroxy-5a.1 *-methyleneoxy-2-methyl-9a-propyl-6.7- 
benzomorphan (3.54)
A solution of 3.53 (3.8g, 0.013 mol) in purified CHCl^ (150 ml) was 
added over 5 minutes to a stirred solution of boron tribomide 
(34.45g, 0.138 mol) in purified CHCl^ (150 ml). After stirring for 
1 hour at 20°C, the mixture was poured on to a stirred mixture of 
ice (200g) and concentrated aqueous ammonia (50 ml). The two 
layers were seperated and the aqueous layer further extracted with 
CHCl^ (2 x 200 ml). The combined organic layers were dried (MgSO^) 
and solvent removed to give 3.54 (3.0g, 832) as a pale brown solid. 
This crystallised from Me2C0 as colourless prisms, m.p. 180-1°C.
The hydrochloride crystallised from EtOAc-EtOH, m.p. 172-4°C.
The liberated free base gave [“ 3^ -59° (£ 1, 952 EtOH)
EIMS m/z 273 (M+)
0.8 - 2.8 8 (m, 18 aliphatic H)
including 2.4 8 (s, 3H, NCH3)
3.1 8 (m, 2H, NCH2)
4.25 8 (ABq, J=8Hz, 2H, 0CH2C)
6.45 8 (ABq, J=8Hz, 2H, 2 x ArH)
7.5 8 (br s, 1H, OH, exchanges with D20)
13-^C NMR See table 3.4
Analysis See table 3.5
(-)-8-Acetoxy-5a.1 *-methyleneoxy-2-methyl-9a-propyl-6.7- 
benzomorphan (3.55)
To a solution of 3.54 (0.8g, 0.003 mol) in anhydrous THF (40 ml) 
was added triethylamine (4 ml) followed by dropwise addition of 
acetyl chloride (4 ml). The mixture was stirred at 20°C for 30 
minutes, then filtered and solvent removed to give a crude residue. 
This was taken up in 1M HC1 (50 ml), washed with Et20 (3 x 50 ml; 
discarded) basified with NaHC03 and extracted with Et20 (3 x 50 
ml). The combined ethereal extracts were dried (MgSO^) and solvent 
removed to give 3.55 (0.6g, 652) as a pale yellow oil. The 
hydrochloride crystallised from Et20-Et0Ac as needles, m.p.
144-8°C.
The liberated free base had [<*3^ ° -52° (£ 1, 95Z EtOH)
EIMS m/z 315 (M+)
0.7 - 2.5 8 (m, 19 aliphatic H)
including 2.25 5 (s, 3H, OCOCH3)
and 2.4 8 (2, 3H, NCH3)
3.0 5 (m, 2H, NCH2)
4.45 8 (ABq, J»8Hz, 2H, 0CH2C)
6.58 8 (ABq, J=8Hz, 2H, 2 x ArH)
13C NMR See table 3.4
Analysis See table 3.5
(-) -2’ -Hydroxy- 5a. 1 * -methvleneoxv-9a-propyl-6. 7-benzomorphan (3.56)
A mixture of 3.54 (1.3g, 0.0048 mol), freshly distilled 
2,2,2-trichloroethylchloroformate (7.4 ml, 0.023 mol), anhydrous 
K2C<^ 3 anc* anhydrous toluene (130 ml) was refluxed for 65
hours. The cooled mixture was filtered, solvent removed, and 
excess 2,2,2-trichloroethylchloroformate removed by distillation 
under reduced pressure (100°C @ 0.5 mmHg). The residual oil 
obtained was largly the corresponding N,0.-di
(trichloroethyloxycarbonyl) derivative. This was dissolved in 90Z 
acetic acid (87 ml); zinc dust (4.3g) was added and the mixture 
stirred vigorously at 20°C for 16 hours. The mixture was filtered, 
basified with Na2C0j and extracted with CHCl^ (3 x 100 ml). The 
combined extracts were dried (MgSO^) and solvent removed to give 
3.56 (lg, 81Z) as a pale yellow oil. This was used for subsequent 
reactions without further purification.
(-)-2-Ally1-2 *-hydroxy-5a.1 *-methyleneoxy-9a-propyl-6.7-
benzomorphan (3.57)
A mixture of crude 3.56 (lg, 0.004 mol), allyl bromide (3.22g,
0.027 mol), anhydrous I^CO^ (2g) and CHCl^ (75 ml) was heated at 
60°C for 3 hours. The cooled mixture was filtered and solvent 
removed to give a crude yellow oil (l.lg). This was taken up in 2M 
NaOH (100ml) and washed with Et£0 (3 x 100 ml). The combined 
ethereal layers were extracted with 2M NaOH (50 ml). The combined 
aqueous layers were acidified with dilute HC1, washed with Et20 
(3 x 100ml; discarded) basified with 10Z aqueous ammonia solution 
and extracted with Et20 (5 x 100 ml). The combined ethereal layers 
were dried (MgSO^) and solvent removed to give 3♦57 (0.2g, 14Z) as 
a colourless solid, m.p. 135-137°C. The hydrochloride crystallised 
from Me2CO-EtOH-Et20, and had m.p. 245-6°C.
The liberated free base gave -90° (c. 1, 95Z EtOH)
1H NMR 0.7 - 3.5 8 (m, 15 aliphatic H)
4.18 8 (ABq, J~8Hz, 2H, 0CH2C)
4.8 - 5.4 5 (m, 2H, CH - CH2)
5.6 - 6.1 8 (m, 1H, CH - CH2)
6.5 8 (ABq, J=8Hz, 2H, 2 x ArH)
7.65 8 (br s, 1H, OH, exchanges with D2O)
13C NMR See table 3.4
Analysis See table 3.5
(-) -2 *-Hydroxy-5at 1 *-methyleneoxy-2-phenethyl-9a -propyl-6.7-
benzomorphan (3.58)
A mixture of crude 3.56 (0.6g, 0.0023 mol) anhydrous ethanol (15 
ml), phenethyl bromide (0.94g, 0.0051 mol) and anhydrous (lg)
was refluxed for 8 days. The cooled mixture was filtered and 
solvent removed to give a semi-solid residue (0.95g). This was 
dissolved in 6M HC1 (100 ml), washed with Et20 (3 x 100 ml; 
discarded), basified with Na2C03 and extracted with Et20 (5 x 100 
ml). The combined ethereal extracts were dried (MgSO^) and solvent 
removed to give 0.7g of largely N,0,-dialkylated product. This was 
dissolved in purified CHCl^ and added to a stirred solution of 
boron tribromide (12.5g, 0.05 mol) in purified CHCl^ (100 ml). The 
mixture was stirred at 20°C for 5 hours then poured into a stirred 
mixture of ice (lOOg) and concentrated aqueous ammonia (20 ml).
The 2 layers were separated and the aqueous layer further extracted 
with CHCl^ (2 x 100 ml). The combined organic layers were dried
(MgSO^) and solvent removed to give crude 3.58 (0.6g) as a light
brown solid. This was chromatrographed on silica gel (8g) using 
CHCl^ as eluant. 3.58 (0.2g, 24Z) was obtained as a light brown 
solid, m.p. 87-90°C. The hydrochloride crystallised from Me2C0 as 
needles, m.p. 270-5°C (dec).
20
The liberated free base gave [a] -68° (c. 1, 95Z EtOH)
D
1H NMR 0.8 - 3.6 8 (m, 19 aliphatic H)
including 3.0 8 (m, 2H, CH2Ph)
4.35 8 (ABq, J=8Hz, 2H, 0CH2C)
6.65 8 (ABq, J=8Hz, 2H, 2 x ArH)
7.15 8 (s, 5H, 5 x ArH)
7.45 8 (br s, 1H, OH, exchanges with D20)
13C NMR See table 3.4
Analysis See table 3.5
(-)-5a .1 *-Methyleneoxy-2-methyl-9a -propyl-6.7-benzomorphan (3.59)
A mixture of 3.54 (3.6g, 0.0132 mol),
5-chloro-l-phenyl-lH-tetrazole (2.17g, 0.015 mol) and anhydrous 
K2CO3 (3.6g) in anhydrous acetonitrile (150 ml) was refluxed for 48 
hours. The cooled mixture was filtered and solvent removed to give 
a crude residual oil. This was hydrogenated in a Parr apparatus at 
200 psi and 60°C for 3 days over 5Z palladium on carbon (5g). 
Filtration of catalyst and removal of solvent gave a crude residue 
which was partitioned between EtOAc (200 ml) and 2N NaOH (100 ml) . 
The aqueous layer was separated and further extracted with EtOAc (2 
x 100 ml). The combined acidic layers were washed with Et20 (2 x 
100 ml; discarded), basified with Na2C03 and extracted with Et20 (5 
x 200 ml). The combined ethereal layers were dried (MgSO^) and 
solvent removed to give 3.59 (3g, 88Z) as a yellow solid. The 
oxalate crystallised from EtOAc-EtOH and had m.p. 139-40°C. The
hydrochloride crystallised from EtOAc-EtOH and had m.p. 205-7°C.
20
The liberated free base gave [<*]q - 100° (c. 0.5, 95Z EtOH).
1H NMR 0.8 - 3.25 8 (m, 18 aliphatic H)
including 2.4 8 (s, 3H, NCHg)
4.18 8 (ABq, J=8Hz, 2H, 0CH2C)
6 . 4 5 - 7 . 2  8 (m, 3H, 3 x ArH)
13C NMR See table 3.4
Analysis See table 3.5
186
(-)-l -Hydroxy-2.5a-dimethyl-9a -propyl-6.7-benzomorphan (3.60)
To a stirred mixture of LAH (1.8g) in anhydrous THF (75ml) was 
added a solution of 3.59 (0.9g, 0.0035 mol) in anhydrous THF 
(75 ml) and the mixture heated under reflux for 3 days. The cooled 
mixture was added dropwise to a stirred mixture of saturated 
aqueous Na2C03 (200 ml) and CHCl^ (500 ml). The organic layer was 
separated and further extracted with CHCl^ (2 x 200 ml). The 
combined organic layers were dried (MgSO^) and solvent removed to 
give 3.60 (0.8Ag, 932) as a yellow semi solid. This crystallised 
from EtOAc-Petroleum Ether (60-80°C) as white crystals, m.p.
208-210°C. [a]*0 -50° (c.0.5, MeOH).
The hydrochloride crystallised from EtOAc-EtOH and had m.p.
155-158°C.
AH NMR (DMSO-d6)
1.8 6 (m, 16 aliphatic H)
2.25 6 (s, 3H,, n c h 3)
2.75 5 (m, 2H,, NCH2)
6.9 6 (m, 3H, 3 x ArH)
8.8 & (br s, 1H, OH)
13C NMR See table 3.A
Analysis See table 3.5
187
(-)-2,5a-Dimethyl-l*-methoxv-9a-propyl-6,7-benzomorphan (3.61)
To a stirred solution of 3.60 (0.83g, 0.0032 mol) in anhydrous MeOH 
(10 ml), at 0°C, was slowly added a solution of diazomethane (~6g) 
in Et20 over 2 hours. After the end of the addition the solution 
was stirred for a further 6 hours at 0°C, then allowed to warm to 
room temperature overnight. Remaining solvent was then removed to 
give an orange semi-solid residue. This was taken up in Et20, 
filtered and filtrate evaporated to yield an orange/yellow semi­
solid residue. This was taken up in petroleum ether (30-40°C) and 
cooled to -78°C. After 1 hour at this temperature the mixture was 
filtered and filtrate evaporated to give crude 3.61 (0.23g). This 
was chromatographed on silica gel (lOg) using
toluene:dioxan:EtOH:aqueous ammonia (50:40:5:1) as eluant. 3.61 
(0.09g, 10Z) was obtained as a yellow oil. The oxalate 
crystallised from Me2C0 and had m.p. 50°C.
90
The liberated free base gave [a]^ -12° (c. 1, Me2C0)
EIMS m/z 273 (M+)
0.7 - 2.2 8 (m, 16 aliphatic H)
2.42 8 (s, 3H, NCH3)
2.5 - 3.5 8 (m, 2 aliphatic H)
3.82 8 (s, 3H, 0CH3)
6.5 - 7.4 8 (m, 3H, 3 x ArH)
13C NMR See table 3.4
I No C,H,N data available )
25C-)-4.6-Dihydroxy-5-homo-5a-oxa-N-methylmorphinan (3.62)
To a solution of 3.50 (O.llg, 0.0035 mol) in freshly distilled THF 
(20 ml) was added diisobutylaluminium hydride in toluene (2 ml of a 
1.5M solution). After stirring the mixture for 2 hours at 20°C, a 
saturated solution of ammonium chloride (10 ml) was added and the 
mixture was brought to greater than pH9 by the addition of Na2C03 
solution. The aqueous layer was then continuously extracted for 24 
hours with CHCl^. Drying of the combined organic layers with MgSO^ 
followed by removal of solvent, gave crude 3.62 as a pale yellow 
solid, which was chromatographed on silica gel (2.5g), using EtOH 
as eluant. 3.62 (0.03g, 272) was obtained as a colourless solid 
which crystallised from Me2C0, m.p. 149°C. The hydrochloride 
crystallised from EtOAc-EtOH and had m.p. 150°C.
The liberated free base gave -20°C (£ 0.2, 952 EtOH)
EIMS m/z 319 (M+)
IR (KBr) 1605 cm"1 (weak) (Ar-H) 
3420 cm"1 (broad) (0-H)
1H NMR 1.3 - 2.2 8 (m, 10 aliphatic H)
2.36 8 (s, 3H, NCH3 )
2.80 8 (m, 2H, NCH2)
3.80 8 (s, 3H, 0CH3)
4.05 8 (m, 1H, CHOH)
4.6 - 5.1 8 (m, 2H, CE^OCHOH)





TABLE 3 . 4  13C NMR DATA OF 3 . 4 6 - 3 . 6 2
a
Compound Ca C4 C8 °3 Ca <1 C9 C5 C5’ N-CH3
c ■
2 V  V  c y  c4’ c6* c /
3.46 21.8 15.4 23.9 29.9 46.2 119.1 55.2 44.4 49.1 198.7 42.6 56.1 142.9 145.0 119.1 110.4 121.8 129.3
3.50 23.2b 15.5 23.7b 33.6 46.5 119.9 55.1 46.5 41.3 70.0 42.6 56.1 143.9 145.5 119.0 109.2 124.8 130.7
3.51 19.3 32.3 22.6 36.5 46.7 172.9 58.1 43.0 44.0 80.9 42.2 56.3 142.3 145.9 113.4 118.8 126.9 129.7
3.52 19.3 30.7 23.7 36.4 46.8 62.1 58.2 42.9 44.0 81.0 42.2 56.4 142.6 145.8 113.2 118.6 127.0 130.0
3.53 19.4 20.9 29.9 36.7 47.0 14.3 58.4 43.1 44.2 81.2 42.5 56.4 142.3 145.9 113.1 118.6 127.4 130.3
3.54 19.7 20.7 29.9 35.9 47.0 14.4 58.2 42.7 44.1 80.9 41.7 139.1 145.0 117.0 119.0 125.5 129.9










3.58 20.5b 20.6b 29.7 34.7b 44.2 14.2 57.4 40.3 45.8 80.7




3.59 20.lb 20.9b 29.9 36.7 46.9 14.3 58.4 42.7 43.4 80.6 43.1 158.4 106.3b 128.0b 118.1b 128.8b 141.3
3.60 d 21.8 25.1 30.8 40.4 49.0 16.0 56.1 50.4 36.7 28.8 44.3 158.0 115.lb 127.3b 120.2b 128.8b 139.2
3.61 20.5 23.9 29.3 38.6 47.8 14.4 55.4 48.9 35.3 26.2 42.4 159.1 109.2b 126.0b 120.4b 129.6b 139.2
3.62 23.7 25.5 32.8 35.3 47.2 96.2 59.2 51.2 41.3 67.8 42.3 56.1 144.5b 144.8b 118.4b 108.7b 124.4b 131.3b
a : Free base in CDCl^ with THS as reference unless stated otherwise 
b : Uncertain assignment, c : CD3CN solvent, d : DMSO-d6 solvent 
e : NCH2 CH2  signal 3*
3 "
190












C18H22N2°3 Calc 68.77 7.05 8.91
Found 68.69 7.08 9.06
C20H27N04 *H2C2°4 Calc 60.68 6.71 3.22
Found 60.54 6.83 3.21
C18H25N03 ,HC1,# i2° Calc 61.97 7.80 4.01
Found 61.96 7.48 3.77
C18H25N02*HC1 Calc 66.76 8.09 4.32
Found 66.32 8.15 4.03
C17H23N02 ,HC1 Calc 65.90 7.81 4.57
Found 65.50 7.91 4.40
C19H25N03*HC1* ^ H2° Calc 60.23 7.71 3.70
Found 59.67 7.53 3.82
C19H25N02 ,HC1,# i2° Calc 66.17 7.89 4.06
Found 65.83 7.45 4.19
C24H29N02 ,HC1 Calc 72.07 7.56 3.50
Found 72.18 7.72 3.24
C17H23N0,H2C2°4 Calc 65.69 7.25 4.03
Found 65.13 7.64 3.60
3.60 C17H25N0 Calc 78.72 9.71 5.40
Found 78.47 9.63 5.34
3.62 C18H25N04 Calc 67.69 7.89 4.38
Found 67.30 7.99 4.36
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PIPERIDINE INTRODUCTION
Pethidine 4♦1 was originally synthesised in the 1930s during a 
search for spasmolytic drugs to replace atropine. It soon became 
apparent that pethidine possessed useful narcotic analgesic 
properties, and it has since become one of the most widely used 
synthetic narcotic analgesics. Due to its relatively short 
duration of action and moderate potency (approximately 1/7 that of 
morphine) it is widely employed in the control of labour pain.'*’
Ph
R
*r ■ I n —vV2UI
4 . 2  R=OCOEt
The reversed ester of pethidine 4.2 is approximately 10 times more
2
potent than pethidine itself both in rodent tests and in man. The 
introduction of a 3-methyl substituent gives rise to the a-trans 





4 . 3  4 . 4
] 11
Racemic a-prodine 4.3 was previously marketed as Nisentil (now 
withdrawn) and is approximately equipotent with the des-methyl 
parent 4.2. whilst racemic J3-prodine 4.4 is several times more 
potent. Resolution of J$-prodine into its 2 antipodal forms showed
3
the ( + ) antipode to be approximately twice as potent as the (-).
Further studies revealed that the case of methyl was unique in that 
the a-trans derivative was the more potent when larger alkyl groups
4
were substituted at the 3-position (table 4.1).
R
a (_t ransj 






n -Pr 2.0 14.7






TABLE 4.1 8 (ED50 mg /kg IVHP)
EFFECT OF INCREASING ALKYL CHAIN LENGTH 
ON ANALGESIC ACTIVITY OF SOME 
3■ALKYLPI PER IDINE DERIVATIVES
(The a-3-allyl derivative is particularly potent: this is generally 
thought to be a consequence of enhanced binding of the allyl group 
to the receptor).
Over the past 20 years a large number of both mono and di (mostly) 
methyl substituted analogues of pethidine reversed esters have been 
reported. Most have been unambiguously configurationally and 
conformationally characterised using X-ray crystallographic and 
other methods, making it possible to discover whether the wide 
ranging potency variations could be rationalised in terms of the 
stereochemical requirements of the analgesic receptor.^
The results of this analysis will be summarised in this 
introduction. They have already been justified elsewhere largely 
in terms of a fit of the equatorial 4-phenyl chair conformation of 
the molecule at the receptor site rather than as a consequence of 
variation in metabolism or transport in vivo♦^
Using biochemical nomenclature 7, the two sides of the ester 4.5 
may be described as prochiral 4S and prochiral 4R.





If an alkyl group is introduced into the Pro-4S side the C-4 carbon 
atom becomes asymmetric and acquires an S configuration
Q
(Cahn-Ingold-Prelog convention ). Similarly, introduction of an 
alkyl group into the Pro-4R side gives C-4 an R configuration 
(figure 4.1). The potency data available on 3-alkylprodine 
derivatives tends to show that the opioid receptor discriminates 
between the Pro-R and Pro-S sides of the molecule. Thus, it is 
found that the more potent antipodes of a-3-alkyl 4.5 all have the 
same configuation when R = methyl, ethyl or propyl. Structure 
4.6 shows the more (3R, 4S) and 4.7 the less (3S, 4R) potent 












TABLE 4.2 9 (ED50 mg/kg MHP)
ANALGESIC ACTIVITIES OF SOME 
3 -a- ALKYL SUBSTITUTED PI PER IDINES








FIGURE 4 .1  2
The results shown in the table 4.2 are consistent with the 
explanation that the molecule presents the Pro-4R side to the 
receptor. All the 4.6 derivatives therefore have very similar 
(high) potencies as their 3-R substituents do not hinder the 
approach to the receptor as do those of the 4.7 derivatives. This 
gives an essentially passive role to an 3-a-alkyl group in the 
Pro-4S side of the molecule. Consistent with this theory is the 
fact that 4.8 is inactive.^"®
Investigations of derivatives with methyl substituents in the 2 
position have found a significant potency reduction when an 
equatorial methyl is placed in the Pro-4S side of the molecule as 
in 4.10 (ED^q 5.5mg/kg), whereas 2-eq-methyl placed in the Pro-4R 





4 .9  4 .1 0
The cis-2.6-disubstituted derivative 4♦11 is also consistent with 
this analysis, being inactive.^-1
Ph
Me,
4 . 1 1
OCOEt
When a 2-methyl substituent is placed axially as in various
disubstituted derivatives, activity is retained as exemplified by
12the tropane analogue 4.12 which is slightly more potent than the 
corresponding unsubstituted prodine (4.2 with R=0C0Me). This 
insensitivity of the receptor towards axial 2-methyl is in marked 
contrast to its discrimination between equatorially placed 2-methyl 
substituents, as previously outlined.
OCOEt \
The overall sensitivity of the receptor towards methyl substituents 
in pethidine reversed esters may therefore be summarised as in A .13 






4 . 1 3
OCOR
PIPERDINE DISCUSSION
In a recent study of the effect of methyl substitution in the 
piperidine ringe of pethidine reversed ester derivatives, a 
consistent set of structure-activity relationships was developed on 
the basis of the interaction of methyl groups with the opioid 
receptor. The absolute orientations of methyl groups which favour 
or have little influence with the receptor have been summarised in 
structure A .13 (see introduction).
On the basis of this analysis it should follow that the antipodes 
of (±)-l-trans-2.6-trimethyl-A-phenyl-A-propionoxvpiperidine 
hydrochloride A .1A (the antipodal forms of which are illustrated by 
A .15 and A .16), should show a large potency difference with the 











4 U 5  (2S, 6S) 4^16 (2R, 6R)
This discussion describes the synthesis and resolution of 4.14
13into its 2 antipodal forms.
Chemistry
The required 1,2,6-trimethylpiperidone 4.17 was obtained by a 
Mannich reaction using dimethyl acetonedicarboxylate, acetaldehyde 
and methylamine hydrochloride (scheme 4.1 ^  ). Reaction of 4.17 
with phenyllithium in anhydrous ether followed by treatment with 
acetic anhydride gave the corresponding
4-acetoxy-l, 2, 6-trimethyl-4-phenylpiperidine 4.18. The NMR 
spectrum indicated that 4.18 had the trans configuration. Doublets 
at 8 = 1.03 and 1.09 ppm were assigned to the axial and equatorial 
methyl groups respectively (figure 4.2). This was supported by the 
22.5 MHz NMR spectrum of 4.18 which showed that four 
magnetically inequivalent methyl groups were present in the 
molecule (figure 4.3).
Resolution of 4.18 using (-)-tartaric, (-)-dibenzoyltartaric,
(-)-ditoluoyltartaric, (+)-camphorsulfonic and 
( + )-bromocamphorsulfonic acid was attempted without success. 
Reduction of the acetyl group in 4.18 with lithium aluminium 
hydride (LAH) in anhydrous ether gave the corresponding piperidinol 
4.19. This was successfully resolved using a molar quantity of 
(-)-dibenzoyl-L.-tartatic acid with methanol as solvent. The 
optical activity of the salt remained constant after three 
crystallisations. The (-) base was then recovered from the 
crystallised salt. The base recovered from the mother liquors was 
mixed with a molar quantity of (+)-dibenzoyl-D-tartaric acid and 
the resulting salt was crystallised three times from methanol to 















1 H 60 MHz NVIR 
SPECTRUM OF 4^18  
(C D C I3 so I v e n t , 









13 C 2 2 . 5  MHz M\flR 
SPECTRUM OF 4 . 1 8  
(C D C I3 s o l v e n t ,  
TMS r e f . )
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The (+) base was liberated from this salt and found to have a
similar (but opposite) optical rotation to the (-) base (see
experimental). Attempts to esterify the resolved piperidinols
using acetic anhydride or acetyl choride gave mainly the dehydrated
product 4 .20 tbut reaction with acetic or propionic anhydride at
1420°C m  the presence of dimethylaminopyridine (DMAP) was 
successful. Thus, reaction of (-) or (+) 4.19 with an excess of 













4 . 2 0  4 . 2 1
SCHEME 4 .2  13
In order to find the absolute configuration of the (-) and (+) 
esters 4.21. X-ray crystallography was employed using the 
hvdrobromide salt of (-) 4.19 ♦ The full details of the analysis 
(which are published elsewhere ^ ) indicated that the absolute 







Since the (-) piperidinol 4.19 yielded the (-) ester 4♦21 and (+)
4♦19 gave (+) 4.21. the absolute configurations are 2S, 6S for (+)
4.21 and 2R, 6R for (-) 4.21 as in diagrams 4.15 and 4.16 
respectively.
Biological Activity
The results of testing racemic A .21 and (-) and (+) A .21 are shown 
in table A.3. The ( + ) antipode of A.21 was approximately A times 
more active than pethidine in the MHP whilst the (-) antipode of 
A .21 was inactive at 20 mg/kg. A similar pattern of activity was 
seen in the tail flick and phenylquinone writhing tests with the 
(+) antipode (configuration 2S, 6S) showing significantly higher 
potency than the (-) antipode.
Conclusion
The more potent antipode of
(±)-l-trans-2.6-trimethvl-A-phenvl-A-propionoxypiperidine was shown 
to have the absolute configuration 2S, 6S, which is consistent with 
the original hypothesis on the allowed pattern of methyl 
substitution in pethidine reversed esters.
IA  B L E_ 4 3 _ 
ANALGESJC_ACTiyiTXES_OF_iA2_i_i+l__&_i-l_4^ 21
Compound® MHPb MTFC PPQd
(±)4 .21 1.5(1.1-2.1) 2.7(1.0-7.5) 0.1(0.03-0.5)
(+)4.21 1 .1 (0 .9-1.3) 0.7(0.2-2.0) 0.2(0.07-0.7)
(-)4.21 IAe (5&20) 11.0(6.8-17.8) 3.0(1.9-4.7)
KEY FOR TABLE 4.3
a : Compounds tested as hydrochloride salts in water 
b : Mouse hot plate test (EDjq mg/kg) 
c : Mouse tail flick test mg/kg)
d : Phenylquinone writhing test (ED50 mg/kg) 
e : IA-Inactive at the dose levels indicated
Experimental Section
Infra-red spectra were recorded on a Unicam SP1025 spectrometer.
Melting points (uncorrected) were taken on a Gallenkamp melting 
point apparatus.
13C NMR spectra were recorded on a JEOL FX90Q spectrometer 
operating at 22.5 MHz. The multiplicity of the resonances was 
obtained by either off-resonance (partial 1H coupling) spectra, or 
by INEPT (Insensitive Nuclei Enhanced by Polarisation Transfer) 
spectra in which the phase of the signal indicated the number of 
protons attached to each carbon atom.
NMR spectra were recorded using JEOL JNM-PMX 60 SI, JEOL PS100 
and JEOL GX400 spectrometers. NMR samples (as bases unless stated 
otherwise) were prepared in 5mm o.d. tubes as approximately 102 
solutions in CDCl^ (unless stated otherwise) with TMS as reference.
Mass spectra were recorded on a VG 7070E mass spectrometer 
operating at 70 eV (El).
Optical Rotations were measured on an Optical Activity Ltd AA-10 
polarimeter.
Elemental analyses were performed by Butterworths Laboratories 
Ltd., Middlesex.













MgS04 Magnesium Sulphate (anhydrous)
NaOH Sodium Hydroxide






Solvent was removed - denotes evaporation under reduced pressure 
using a rotary evaporator.
1.2.6-Trimethyl-4-piperidone (4.17)^
To a stirred, cooled mixture of dimethylacetone dicarboxylate (100 
ml), and acetaldehyde (64 ml) was added slowly a solution of 
methylamine hydrochloride (37 g) in 1^0 (160 ml) . After stirring 
at ambient temperature for 48 hours, excess acetaldehyde and 1^0 
were removed. To the residual yellow oil obtained was added a 
solution of concentrated hydrochloric acid (250 ml) in 1^0 (150 ml) 
and the resultant solution held at 50°C for 16 hours to complete 
the decarboxylation. The cooled solution was basified with NaOH 
and extracted with C I ^ C ^  (3 x 300 ml). Drying (MgS04) and removal 
of solvent gave a brown oil which was distilled twice to give 4.17 
(23.0 g, 19Z) as a colourless oil b.p. 52-76°C @ 1 mmHg, (lit11b.p. 
80°C § 20 mmHg).
1.03 8 (d, J = 6.5Hz. 3H. trans)
1.18 8 (d, J = 6.5Hz, 3H, cis)
2.28 8 (t, 3H, NCHg, cis)
2.38 8 (t, 3H, NCH^. trans)
4-Acetoxy-l.-(trans)-2.6-trimethyl-4-phenylpiperidine (4.18) ^
To phenyllithium in anhydrous Et20 [made from bromobenzene (111.3g, 
0.71 mol) and lithium (lOg, 1.42 mol), and left to react for 1 
hour], was slowly added a solution of 4.17 (26g, 0.185 mol) in 
anhydrous Et20, and the mixture left to stir at ambient temperature 
for 24 hours.
?] 7
The mixture was cooled and acetic anhydride (100 ml) 
was added slowly over 30 minutes, left to stir for 1 hour, then 
poured onto a mixture of ice (200g) and acetic acid (200 ml). The 
aqueous phase was separated and washed with Et20 (2 x 500 ml). The 
combined ethereal extracts were washed with 50Z acetic acid (3 x 
200ml). The combined aqueous layers were basified with Na2C03 and 
extracted with Et20 (4 x 500 ml). Removal of solvent and drying 
(MgSO^) gave crude 4.18 as a yellow oil. This was dissolved in 
Me2C0 and made acidic by addition of ethereal HC1. The 
hydrochloride salt of 4.18 was filtered and washed with Me2C0.
Liberation of the free base gave 4.18 (26.lg, 54Z) as a yellow oil.
The hydrochloride crystallised from Et0H-Et2O and had m.p.
198-200°C, (lit11 m.p. 198-199°C).
1.03 6 (d, J * 7 Hz, 2H, axCH
1.09 5 (d, J = 7 Hz, 2H, eqCH
1.72 6 (m, 2H, CH2)
1.98 6 (s, 3H, 0C0CH3)
2.35 5 (s, 3H, NCH3)
2.2 - 2. 6 8 (m, 2H, CH2)
2.9 8 (m, 1H, C (Hax)CH3)
3.28 6 (m, 1H, C (Heq)CH3)
7.3 8 (m, 5H, ArH)
13C NMR See table 4.4
4-Hydroxv-l-(trans)-2.6-trimethyl-4-phenylpineridine (4.19)
To a stirred mixture of LAH (3.0g) in anhydrous (100 ml) was
slowly added a solution of 4.18 (20g, 0.09 mol) in anhydrous Et20 
(100 ml) and the mixture stirred for 30 minutes at ambient 
temperature. A saturated aqueous solution of Na2C03 (20 ml) was 
added slowly dropwise with cooling and the mixture diluted with 
CHCl^ (500 ml). Drying (MgSO^), filtration, washing of the cake 
with CHClg and removal of solvent gave 4♦19 (16.3g, 68Z) as a pale 
yellow solid, m.p. 90-3°C, (lit*^ m.p. 95°C).
The hydrobromide salt crystallised from EtOAc-EtOH as small prisms 
and had m.p. 156-7°C. These were subsequently used in the X-ray 
crystallographic analysis.
1.03 8 (d, J « 7 Hz, axCH3)
1.09 8 (d, J * 7 Hz, eqCH3)
1.7 8 (m, 2H, c h 2 )
1.75 8 (br s, OH)
2.2 - 2. 5 8 (m, 2H, CHZ)
2.32 8 (s, 3H, n c h 2)
2.6 8 (m, 1H, C (Hax)CH3)
3.05 8 (m, 1H, C (Heq)CH3)
7.3 8 (m, 5H, ArH)
13C NMR See table 4.4
(-)-4-Hydroxv-l-(trans) -2.6-trimethyl-4-phenylpiperidine (-)4.19
A mixture of racemic 4.19 (16.7g, 0.076 mol) and
(-)-dibenzoyl-L-tartaric acid monohydrate (28.7g, 0.076 mol) were
dissolved in warm HeOH (130 ml), filtered and left to crystallise
overnight. After 3 crystallisations of the salt from MeOH, 6.8g
20were obtained having a constant optical rotation, [a] - 76.0°
(589 nm), - 351° (365 nm) (c. 1, MeOH).
Liberation of the free base gave (-) 4.19 (2.5g, 30Z) as a white
90
solid. [a] ^  - 17.0° (589 nm), -44.0 (365 nm), (c 1, MeOH).
( + )-4-Hydroxv-l-(trans)-2.6-trimethyl-4-phenylpiperidine (+)4.19
To 12.7g of the free base obtained from the mother liquor remaining
after filtering off the first crop of (-)
4.19(-)-dibenzovl-L-tartrate salt was added
(+)-dibenzoyl-D-tartaric acid (21.8 g, 1 equivalent) and the
mixture dissolved in warm MeOH and left to crystallise as before.
After 3 crystallisations from MeOH, 8.0g were obtained
90
having a constant optical rotation, [a] + 71.0° (589 nm), + 352°
(365 nm). (£ 1, MeOH). Liberation of the free base gave (+) 4♦19
(2.7g, 32Z) as a white solid. [a] + 17.0° (589 nm), + 44.0°
(365 nm), (_c 1, MeOH).
1. (trans)-2.6-Trimethyl-4-phenyl-A-propionoxypiperidine (4.21)
To a stirred solution of 4.19 (0.5g, 0.0023 mol) in propionic 
anhydride (5 ml) was added dimethylaminopyridine (DMAP) (0.15g), 
the resulting solution kept at ambient temperature for 24 hours, 
then poured onto a 502 aqueous solution of acetic acid (50 ml).
The solution was washed with Et20 (3 x 75 ml: discarded), basified 
with Na2C03 and extracted with Et20 (3 x 100 ml). The combined 
ethereal extracts were washed with H20 (10 x 50 ml) to remove DMAP 
then dried (MgSO^) and solvent removed to give 4.21 (0.46g, 73Z) as 
a pale yellow oil, b.p. 100°C § 2mm Hg (dec). The hydrochloride 
crystallised from EtOAc/EtOH and had mp 186-7°C.
IR (KC1,Hydrochloride) 1745 cm-^ (C=0)
1.25 6 (m, 9H, 3 x CH3 )
2.50 5 (m, 6H, 3 x CH2 )
3.25 5 (s, 3H, NCH3)
2.75 5 (m, 1H, C(Hax)CH3)
3.05 5 (m, 1H, C(Heq)CH3)
7.05 5 (m, 5H, ArH)
1^C NMR See table 4.4
Analysis See table 4.5
TABLE 4 .4  13C NMR DATA OF SOME 1 , 2 , 6-TRIMETHYL-4-PHENYLP! PER I DINES
Compound* N-Me C2 C3 CA C5 C6 2 - Me 
axial
6 - Me 
equat­
orial
Aromatics C - 0 c o c h 2 c h 2c h 3
A. 18 39.0 A6.A A5.2 81.9 39.0 5A.8 12.0 20.3 1A5.1, 128.3, 127.0, 12A.3 169.5 - 22.5
A.19 39.1 A7.1 A6.6 73.2 A3. A 5A.8 13.3 19.8 1A9.1, 128.1, 126.7, 12A.5 - - -
A. 21 38.9 A6.A A5.1 81.6 39.1 5A.8 12.1 20.3 1A5.3, 128.3, 127.0, 12A.2 172.8 28.9 8.9
a : Free base in CDCl^ with TMS as reference X5 3
M e ^ T T  ‘'"Me
Analytical Data Table A.5
Compound Formula C H N
4.21 C1? H25 NO,. HC1 Calc 65.48 8.40 4.49
(±) 4.21 Found 65.30 8.37 4.29
(+) 4.21 Found 65.20 8.42 4.28
(-) 4.21 Found 65.46 8.37 4.26
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